NZ789582A - Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof - Google Patents

Abstract

combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.

Description

COMBINATION OF A BCL-2 INHIBITOR AND A MCL-1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF This application is a divisional of New Zealand patent application 750047, which is the al phase entry of PCT international application 2017/068453 filed 21 July 2017 (and published as applications is incorporated herein by reference.

FIELD OF THE INVENTION The present ion relates to a ation of a BCL-2 inhibitor and a MCL1 inhibitor.

The ion also s to the use of said combination in the treatment of cancer, in particular leukaemia, lymphoma, multiple myeloma, neuroblastoma and lung cancer, and more ally acute myeloid leukaemia, T-cell acute lymphobla stic leukemia, B-cell acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma and small cell lung cancer. Also provided are pharmaceutical formulations suitable for the administration of such combinations.

BACKGROUND OF THE INVENTION Apoptosis is a highly regulated cell death pathway that is initiated by various xic stimuli, including oncogenic stress and chemotherapeutic agents. It has been shown that evasion of apoptosis is a rk of cancer and that efficacy of many chemotherapeutic agents is dependent upon the activation of the intrinsic mitochondrial pathway. Three distinct subgroups of the BCL-2 family proteins control the intrinsic apoptosis pathway: (i) the pro-apoptotic BH3 (the BCL-2 homology 3)-only proteins; (ii) the pro-survival members such as BCL-2 itself, BCL-XL, Bcl-w, MCL1 and BCL-2a1; and (iii) the proapoptotic effector proteins BAX and BAK (Czabotar et al, Nature Reviews Molecular cell biology 2014 Vol 15:49-63). Overexpression of the poptotic members of BCL-2 family is ed in many cancers, particularly in hematological malignancies such as mantle cell lymphoma (MCL), follicular lymphoma/diffuse large B-cell lymphoma (FL/D) and multiple myeloma (Adams and Cory Oncogene 2007 Vol 26:1324-1337).

Pharmacological inhibition of the anti-apoptotic proteins BCL-2, BCL-XL and Bcl-w by the recently developed BH3-mimetics drugs such as ABT-199 and 3 has emerged as a therapeutic strategy to induce apoptosis and cause tumor regression in cancer (Zhang et al, Drug Resist Updat 2007 Vol 207-17). Nevertheless, mechanisms of resistance to these drugs have been ed and investigated (Choudhary GS et al, Cell Death and Disease 2015 Vol 6, e1593; doi:10.1038/cddis.2014.525).

Acute myeloid leukaemia (AML) is a y fatal blood cancer arising from clonal transformation of hematopoietic stem cells resulting in paralysis of normal bone marrow function and deaths due to complications from profound pancytopenia. AML accounts for % of all adult leukaemias, with the highest incidence rates occurring in the United States, Australia and Europe (WHO. GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer). Globally, there are approximately 88,000 new cases diagnosed annually. AML continues to have the lowest al rate of all leukaemias, with expected 5-year al of only 24%. Although the standard y for AML (cytarabine in combination with anthracyclines) was conceived over 4 decades ago, the introduction of successful targeted therapies for this disease has remained an elusive goal. Furthermore, there remains a need for a chemotherapy-free treatment option for patients with AML. The concept of targeted therapy in AML has been hampered by the realisation that this disease evolves as a multiclonal hierarchy, with rapid outgrowth of leukaemic sub-clones as a major cause of drug resistance and disease relapse (Ding L et al, Nature 2012 481:506-10). Recent clinical igations have demonstrated the efficacy of BCL-2 inhbibitors in the treatment of AML (Konopleva M et al, American Society of Hematology 2014:118). Although these inhibitors are clinically active, it is likely that other BCL-2 family members will need to be targeted in order to enhance the overall efficacy in AML. In addition to BCL-2, MCL1 has also been identified as an important regulator of cell survival in AML (Glaser SP et al, Genes & development 2012 26:120-5).

Multiple myeloma (MM) is a rare and ble disease that is characterized by the accumulation of clonal plasma cells in the bone marrow (BM) and accounts for 10% of all haematological malignancies. In Europe, there are approximately 27,800 new cases each year. Due to the availability of new agents in recent years including bortezomib and lenalidomide, and autologous stem cell transplant , the survival rate has ed. r, the response to these new agents is ntly not durable and it became an ce that new treatments are needed, especially for relapsed/ refractory patients and patients with unfavorable stic (unfavorable cytogenetic profil). Recent investigations suggest a promising ty of BCL-2 inhibitors in a sub-group of multiple myeloma patients (Touzeau C, t C, Le Gouill S, et al. Leukemia. 2014; 28(1):210- 212). MCL1 has also been identified as an important regulator of cell survival in multiple myeloma (Derenne S, Monia B, Dean NM, et al. Blood. 2002;100(1):194-199; Zhang B, Gojo I, Fenton RG. Blood. 2002;99(6):1885-1893).

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type (25-35%) of Non- n ma with 24 000 new patients/year. DLBCL is a heterogeneous disease with over a dozen subtypes, including double-hit/MYC translocation, Activated B-Cell (ABC) and Germinal Center B-cell (GCB). Modern immune chemotherapy (R-CHOP) cures imately 60% of ts with DLBCL, but for the 40% remaining, there is little therapeutic option and the prognostic is poor. Thus, there is a high medical need to increase cure rates and clinical outcomes in high risk DLBCL such as ABC subtype (35% of DLBCL) that display constitutive activation of the prosurvival NF-κB y.

Neuroblastoma (NB) is the most common extra-cranial solid tumor in infants and children, representing 8%-10% of all childhood tumors stratified currently into low-, intermediate-, or high-risk. It accounts for approximately 15% of all cancer-related deaths in the pediatric population. The incidence of NB is 10.2 cases per million en under 15 years of age, and nearly 500 new cases are reported annually. The median age of diagnosis is 22 months.

Outcomes in patients with NB have improved steadily over the last 30 years with 5-year survival rates rising from 52% to 74%. However, it is estimated that 50-60% of patients in the high-risk group experience relapse, and as such, they have only seen a modest decrease in mortality. The median time to relapse was 13.2 months, and 73% of those who relapsed were 18 months or older. Taken together, NB overall survival rates remain quite abysmal (∼20% at 5 years) despite more aggressive ies (Colon and Chung, Adv Pediatr 2013 58:297-311). The mainstay of treatment ts of chemotherapy, surgical resection, and/or radiotherapy. However, many aggressive NB have developed resistance to chemotherapeutic agents, making the likelihood of relapse quite high (Pinto et al, J Clin Oncol 201533:3008-11). Standards of care for NB depending on risk stratification are frequently carboplatin, cisplatin cyclophosphamide, doxorubicin, etoposide, cytokines (GM-CSF and IL2), and vincristine. Relapse after initial response to chemotherapy is the major reason for treatment failure especially in high-risk NB.

Chemoresistance may derive from the activation of prosurvival BCL-2 proteins (e.g. BCL- 2 and MCL1 proteins). NB express high level of BCL-2 and MCL1 and low level of BCL- XL. Inhibition of BCL-2 sensitizes cell to death and induces NB tumor regression in vivo (Ham et al, Cancer Cell 29:159-172). Antagonisms of BCL-2 and MCL1 e chemotherapy in high-risk NB (Lestini et al, Cancer Biol Ther 2009 8:1587-1595; Tanos et al, BMC Cancer 2016 16:97). Thus, there is strong rational to combine BCL-2 and MCL1 inhibitors in naïve or resistant patients.

The present invention provides a novel combination of a BCL-2 inhibitor and a MCL1 inhibitor. The results show that with the development of potent small molecules targeting BCL-2 and MCL1, highly synergistic pro-apoptotic activity is revealed in y human AML samples (Figure 2A and 17) as well as in AML (Figures 9, 13 and 14), multiple myeloma (Example 4), lymphoma (Figures 4 and 12), neuroblastoma (Figure 10), T-ALL, B-ALL cell lines (Figure 11) and in small cell lung cancer cell lines es 15 (a)-(e)).

We also show that combined BCL-2 and MCL1 targeting in vivo is efficacious at tolerated doses in AML and lymphoma xenograft models in mouse and rats (Figures 2, 5, 6, 7, 8 and 16), and dramatically increases time to relapse in AML (Figures 2B and 2C). Furthermore, in clonogenic , we trate that BCL-2+MCL1 targeting is specifically toxic to leukemogenic cells, but not normal hematopoietic stem cells (Figure 3), in contrast to prior MCL1 gene targeting ments in mice. Prior to the development of these potent and selective inhibitors, the ility of targeting both BCL-2 and MCL1, remained uncertain.

Previous lineage-specific on models indicated potential risk to cardiac (Wang X et al, Genes & development. 2013;27(12):1351-1364; Thomas RL et al, Genes & development. 2013;27(12):1365-1377), granulocyte/hematopoietic (Opferman J et al, Science's STKE. 2005;307(5712):1101; Dzhagalov I et al, Blood. 2007;109(4):1620-1626; Steimer DA et al, Blood. 13(12):2805-2815), yte (Dunkle A et al, Cell Death & Differentiation. 7(6):994-1002), neuronal r N et al, Journal of cience. 2008;28(24):6068-6078) and liver function (Hikita H et al, Hepatology. 2009;50(4):1217- 1226 ; Vick B et al, Hepatology. 2009;49(2):627-636) resulting from long-term ablation of MCL1. Despite these concerns, weekly, twice weekly and even daily (during 5 consecutive days) intravenous delivery of a new potent short-acting pharmacological inhibitor of MCL1 has recently been shown to be well tolerated and active against a range of cancers in vivo, including AML (Kotschy A et al, Nature. 2016;538(7626):477-482; WO 2015/097123). The short half-life of MCL1 protein may permit sufficient time for its regeneration in critical organs, thereby permitting physiological tolerance to MCL1 inhibitors term exposure (Yang T et al, Journal of cellular physiology. 1996;166(3):523-536). Until now, pulsatile inhibition of BCL-2 and MCL1 mimicking a drug-like effect has not been possible using genetically engineered approaches. The studies using BCL-2 and MCL1 inhibitors ing to the present invention provide proof-of- concept demonstration that intermittent exposure to these drugs may be sufficient to r sis and clinical response among highly sensitive diseases, such as AML, without concurrent toxicity to major organ systems.

The istic effect of targeting both BCL-2 and MCL1 in vitro and in vivo and the non- toxicity to normal marrow production when targeting both anti-apoptotic ns have only been demonstrated through combination of potent small molecule inhibitors. These aspects were not anticipated by the results of gene targeting experiments, which would t that MCL1 deletion is poorly tolerated by hematopoietic stem cells.

SUMMARY OF THE INVENTION The present invention relates to a combination sing (a) a BCL-2 tor of formula Y A2 R5 (I) Rd Rb wherein: ♦ X and Y represent a carbon atom or a nitrogen atom, it being understood that they may not simultaneously ent two carbons atoms or two nitrogen atoms, ♦ A1 and A2, together with the atoms carrying them, form an optionally substituted, aromatic or non-aromatic heterocycle Het composed of 5, 6 or 7 ring members which may contain, in addition to the nitrogen represented by X or by Y, from one to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be tuted by a group representing a en atom, a linear or branched (C1-C6)alkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C1-C6)alkyl group, or A1 and A2 independently of one another represent a hydrogen atom, a linear or branched (C1-C6)polyhaloalkyl, a linear or ed (C1-C6)alkyl group or a cycloalkyl, ♦ T represents a en atom, a linear or branched (C1-C6)alkyl group optionally substituted by from one to three n atoms, a group (C1-C4)alkyl-NR1R2, or a group )alkyl-OR6, ♦ R1 and R2 independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group, or R1 and R2 form with the nitrogen atom carrying them a heterocycloalkyl, ♦ R3 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl group, a (C3-C10)cycloalkyl-(C1-C6)alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, it being tood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated, ♦ R4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched (C1-C6)alkyl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated, ♦ R5 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group, or a linear or branched (C1-C6)alkoxy group, ♦ R6 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ Ra, Rb, Rc and Rd, each independently of the others, represent R7, a halogen atom, a linear or branched (C1-C6)alkoxy group, a y group, a linear or branched (C1-C6)polyhaloalkyl group, a trifluoromethoxy group, -NR7R7', nitro, R7-CO-(C0-C6)alkyl-, R7-CO-NH-(C0-C6)alkyl-, NR7R7'-CO-(C0-C6)alkyl-, NR7R7'-CO-(C0-C6)alkyl-O-, R7-SO2-NH-(C0-C6)alkyl-, R7-NH-CO-NH-(C0-C6)alkyl-, R7-O-CO-NH-(C0-C6)alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (Ra,Rb), ) or (Rc,Rd) form together with the carbon atoms carrying them a ring composed of from 5 to 7 ring members, which may contain from one to 2 hetero atoms selected from oxygen and sulphur, it also being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from halogen and linear or branched (C1-C6)alkyl, ♦ R7 and R7' ndently of one another represent a en, a linear or branched (C1-C6)alkyl, a linear or branched (C2-C6)alkenyl, a linear or branched (C2-C6)alkynyl, an aryl or a heteroaryl, or R7 and R7' together with nitrogen atom carrying them form a heterocycle composed of from 5 to 7 ring s, it being understood that when the compound of formula (I) contains a y group, the latter may be ally converted into one of the following groups: –OPO(OM)(OM’), M)(O-M1+), –OPO(O-M1+)(O-M2+), –OPO(O-)(O-)M32+, –OPO(OM)(O[CH2CH2O]nCH3), or –OPO(O-M1+)(O[CH2CH2O]nCH3), wherein M and M' independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl or a heterocycloalkyl, both composed of from 5 to 6 ring members, while M1+ and M2+ independently of one another represent a pharmaceutically acceptable monovalent cation, M32+ represents a ceutically acceptable divalent cation, and n is an integer from 1 to 5, it being understood that: - "aryl" means a , naphthyl, biphenyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen ding quaternary nitrogens), - alkyl" means any mono- or bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10 ring members, - ocycloalkyl" means any mono- or bi-cyclic, non-aromatic, condensed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO2 and nitrogen, it being possible for the aryl, aryl, cycloalkyl and heterocycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy to be substituted by from 1 to 3 groups selected from: linear or branched (C1-C6)alkyl optionally substituted by a hydroxyl, a morpholine, 3difluoropiperidine or a fluoropyrrolidine; (C3-C6)spiro; linear or branched (C1-C6)alkoxy optionally substituted by a morpholine; (C1-C6)alkyl-S-; yl; oxo; N-oxide; nitro; cyano; -COOR'; ; NR'R''; linear or branche d (C1-C6)polyhaloalkyl; trifluoromethoxy; (C1-C6)alkylsulphonyl; halogen; aryl optionally substituted by one or more halogens; heteroaryl; aryloxy; arylthio; lkyl; heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R' and R'' independently of one another represent a hydrogen atom or a linear or branched )alkyl group optionally substituted by a methoxy, it being possible for the Het group defined in formula (I) to be substituted by from one to three groups ed from linear or branched (C1-C6)alkyl, hydroxy, linear or branched (C1-C6)alkoxy, NR1'R1" and halogen, it being understood that R1' and R1" are as defined for the groups R' and R'' mentioned hereinbefore, or its enantiomers, diastereoisomers, or addition salts thereof with a pharmaceutically acceptable acid or base, and (b) a MCL1 inhibitor.

Said compounds of formula (I), their sis, their use in the treatment of cancer and pharmaceutical formulations thereof, are described in WO 2013/110890, incorporated by reference.

In n embodiments, the MCL1 inhibitor is selected from 477 (Cell Death and Disease 2015 6, e1590; doi:10.1038/cddis.2014.561) and the compounds described in WO 2015/097123, reference.

The present invention also s to a combination comprising (a) a BCL-2 inhibitor and (b) a MCL1 inhibitor of a (II): wherein: ♦ A represents a linear or branched (C1-C6)alkyl group, a linear or ed (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)alkoxy group, -S-(C1-C6)alkyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a cyano, -NW10W10’, -Cy6 or an halogen atom, ♦ W1, W2, W3, W4 and W5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or ed )polyhaloalkyl, a hydroxy group, a linear or branched (C1-C6)alkoxy group, -S-(C1-C6)alkyl group, a cyano, a nitro group, -alkyl(C0-C6)-NW8W8’, -O-Cy1, -alkyl(C0-C6)-Cy1, -alkenyl(C2-C6)-Cy1, -alkynyl(C2-C6)-Cy1, -O-alkyl(C1-C6)-W9, -C(O)-OW8, -O-C(O)-W8, -C(O)-NW8W8’, -NW8-C(O)-W8’, -NW8-C(O)-OW8’, -alkyl(C1-C6)-NW8-C(O)-W8’, -SO2- NW8W8’, -SO2-alkyl(C1-C6), or the substituents of one of the pairs (W1, W2), (W2, W3), (W1, W3), (W4, W5) when grafted onto two adjacent carbon atoms, form together with the carbon atoms carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that ing ring may be substituted by a group selected from a linear or branched (C1-C6)alkyl group, -NW10W10’, -alkyl(C0-C6)-Cy1 or an oxo, ♦ X’ represents a carbon or a nitrogen atom, ♦ W6 represents a hydrogen, a linear or branched (C1-C8)alkyl group, an aryl, an heteroaryl group, an arylalkyl(C1-C6) group, an heteroarylalkyl(C1-C6) group, ♦ W7 ents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, -alkyl(C1-C6)-Cy3, -alkenyl(C2-C6)-Cy3, yl(C2-C6)-Cy3, -Cy3-Cy4, -alkynyl(C2-C6)-O-Cy3, -Cy3-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy4, an halogen atom, a cyano, -C(O)-W11, -C(O)-NW11W11’, ♦ W8 and W8’ independently of one another represent a hydrogen atom, a linear or ed (C1-C6)alkyl group, or -alkyl(C0-C6)-Cy1, or (W8, W8’) form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in on to the nitrogen atom from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, or a linear or ed (C1-C6)alkyl group and it being understood that one or more of the carbon atoms of the le tuents, may be deuterated, ♦ W9 represents -Cy1, -Cy1-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)-NW8-alkyl(C0-C6)-Cy2, y2-O-alkyl(C0-C6)-Cy5, -C(O)-NW8W8’, -NW8W8’, -OW8,-NW8-C(O)-W8’, -O-alkyl(C1-C6)-OW8, -SO2-W8, -C(O)-OW8, O)-NH-W8, , or , it being possible for the ammonium so defined to exist as a zwitterionic form or to have a monovalent anionic counterion, ♦ W10, W10’, W11 and W11’ independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ W12 represents a hydrogen or a hydroxy group, ♦ W13 ents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ W14 represents a -O-P(O)(O-)(O-) group, a -O-P(O)(O -)(OW 16) group, a )(OW16)(OW16’) group, a -O-SO2-O- group, a -O-SO2-OW16 group, -Cy7, a -O-C(O)-W15 group, a -O-C(O)-OW15 group or a -O-C(O)-NW15W15’ group, ♦ W15 and W15’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or a linear or branched amino(C1-C6)alkyl group, ♦ W16 and W16’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or an arylalkyl(C1-C6) group, ♦ Cy1, Cy2, Cy3, Cy4, Cy5, Cy6 and Cy7 independently of one another, represent a lkyl group, a heterocycloalkyl group, an aryl or an heteroaryl group, ♦ n is an integer equal to 0 or 1, it being understood that: - "aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and ning from 1 to 3 heteroatoms selected from oxygen, r and nitrogen, - "cycloalkyl" means any mono- or lic non-aromatic carbocyclic group containing from 3 to 10 ring members, - “heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so d and the alkyl, l, l, alkoxy, to be substituted by from 1 to 4 groups selected from linear or branched (C1-C6)alkyl which may be substituted by a group representing a linear or branched (C1-C6)alkoxy which may be substituted by a linear or branched (C1-C6)alkoxy, a linear or branched (C1-C6)polyhaloalkyl, hydroxy, halogen, oxo, -NW’W’’, -O-C(O)-W’, or -CO-NW’W’’; linear or branched (C2-C6)alkenyl group; linear or branched (C2-C6)alkynyl group which may be substituted by a group representing a linear or branched (C1-C6)alkoxy; linear or branched (C1-C6)alkoxy which may be substituted by a group enting a linear or branched (C1-C6)alkoxy, a linear or ed (C1-C6)polyhaloalkyl, a linear or ed (C2-C6)alkynyl, -NW’W’’, or hydroxy; (C1-C6)alkyl-S- which may be substituted by a group representing a linear or branched (C1-C6)alkoxy; hydroxy; oxo; N-oxide; nitro; cyano; -C(O)-OW’; -O-C(O)-W’; ’W’’; -NW’W’’; - (C=NW’)-OW’’; linear or branched (C1-C6)polyhaloalkyl; trifluoromethoxy; or halogen; it being understood that W’ and W’’ independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group which may be substituted by a group representing a linear or branched (C1-C6)alkoxy; and it being understood that one or more of the carbon atoms of the preceding possible substituents, may be deuterated, its enantiomers, diastereoisomers or somers, or addition salts thereof with a pharmaceutically acceptable acid or base.

Said compounds of formula (II), their sis, their use in the treatment of cancer and pharmaceutical ations thereof, are described in which is incorporated by reference.

In certain embodiments, the BCL-2 inhibitor is selected from the following compounds: 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexenyl]methyl}piperazinyl)-N-[(3- 4-{[(oxanyl)methyl]amino}phenyl)sulfonyl][(1H-pyrrolo[2,3-b]pyridin yl)oxy]benzamide (venetoclax or ABT-199); 4-(4-{[2-(4-chlorophenyl)-5,5- dimethylcyclohexenyl]methyl}piperazinyl)-N-(4-{[(2R)(morpholinyl) (phenylsulfanyl)butanyl]amino}(trifluoromethanesulfonyl)benzenesulfonyl] ide oclax or ABT-263); oblimersen (G3139); obatoclax (GX15-070); HA14- 1; (±)-gossypol (BL-193); (-)-gossypol (AT-101); apogossypol; TW-37; antimycin A, ABT-737 (Oltersdorf T et al, Nature 2005 June 2;435(7042):677-81) and compounds bed in 2015/011400, the contents of which are incorporated by reference.

According to a first aspect of the invention, there is provided a ation comprising: (a) a BCL-2 inhibitor of formula (I) as described herein, and (b) a MCL1 inhibitor of formula (II) as described herein.

In another embodiment, the invention provides a combination comprising: (a) nd 1: N-(4-hydroxyphenyl){6-[((3S)(4-morpholinylmethyl)-3,4-dihydro- 2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydro indolizine carboxamide, or a pharmaceutically acceptable salt thereof, and (b) a MCL1 inhibitor, for simultaneous, sequential or te use.

In another embodiment, the invention provides a combination comprising: (a) Compound 4: 5-(5-chloro{[(3S)(morpholinylmethyl)-3,4-dihydroisoquinolin- 2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrolyl)-N-(4- hydroxyphenyl)-1,2-dimethyl-1H-pyrrolecarboxamide, or a pharmaceutically able salt thereof, and (b) a MCL1 inhibitor, for simultaneous, sequential or separate use.

Alternatively, the invention provides a combination comprising: (a) a BCL-2 inhibitor, and (b) Compound 2: (2R){[(5Sa){3-chloromethyl[2-(4-methylpiperazin yl)ethoxy]phenyl}(5-fluorofuranyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[1- (2,2,2-trifluoroethyl)-1H-pyrazolyl]methoxy}phenyl)propanoic acid, for simultaneous, sequential or separate use.

In another embodiment, the invention provides a combination sing: (a) a BCL-2 inhibitor, and (b) Compound 3: (2R){[(5Sa){3-chloromethyl[2-(4-methylpiperazin yl)ethoxy]phenyl}(4-fluorophenyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[2-(2- yphenyl)pyrimidinyl]methoxy}phenyl)propanoic acid, for simultaneous, tial or separate use.

In another embodiment, the invention provides a combination as described herein, for use in the treatment of cancer.

In another embodiment, the invention provides the use of a combination as described herein, in the manufacture of a ment for the treatment of cancer.

In another ment, the invention provides a medicament containing, separately or together, (a) a BCL-2 inhibitor of formula (I) and (b) a MCL1 inhibitor, (a) a BCL-2 tor and (b) a MCL1 inhibitor of formula (II), for simultaneous, tial or separate administration, and wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in effective s for the treatment of cancer.

In another embodiment, the invention provides a method of treating cancer, comprising administering a jointly therapeutically effective amount of: (a) a BCL-2 inhibitor of formula (I) and (b) a MCL1 inhibitor, (a) a BCL-2 inhibitor and (b) a MCL1 inhibitor of formula (II), to a subject in need thereof.

In another embodiment, the invention provides a method for sensitizing a patient who is (i) tory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii), n the method comprises administering a y eutically effective amount of: (a) a BCL-2 inhibitor of formula (I) and (b) a MCL1 inhibitor, (a) a BCL-2 inhibitor and (b) a MCL1 inhibitor of formula (II), to said patient.

In a particular embodiment, the BCL-2 inhibitor is N-(4-hydroxyphenyl){6-[((3S)(4- morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}-N- phenyl-5,6,7,8-tetrahydroindolizine carboxamide hydrochloride (Compound 1, HCl).

In a particular embodiment, the BCL-2 inhibitor is 5-(5-chloro{[(3S)(morpholin ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl- 1H-pyrrolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrolecarboxamide hydrochloride (Compound 4, HCl).

In another ment, the BCL-2 inhibitor is ABT-199.

In another embodiment, the MCL1 inhibitor is (2R){[(5Sa){3-chloromethyl[2- (4-methylpiperazinyl)ethoxy]phenyl}(5-fluorofuranyl)thieno[2,3-d]pyrimidin yl]oxy}(2-{[1-(2,2,2-trifluoroethyl)-1H-pyrazolyl]methoxy}phenyl)propanoic acid (Compound 2).

In another embodiment, the MCL1 inhibitor is (2R){[(5Sa){3-chloromethyl[2- (4-methylpiperazinyl)ethoxy]phenyl}(4-fluorophenyl)thieno[2,3-d]pyrimidin yl]oxy}(2-{[2-(2-methoxyphenyl)pyrimidinyl]methoxy}phenyl)propanoic acid (Compound 3).

BRIEF DESCRIPTION OF THE FIGURES Figure 1. Expression of BCL-2 and MCL1 is prevalent in AML. 7 AML cell lines and 13 primary AML samples with >70% blasts were immunoblotted for indicated proteins, showing that BCL-2 and MCL1 proteins are dominantly expressed in contrast to BCL-XL, which was expressed in a lower proportion of s.

Figure 2. ed BCL-2/MCL1 targeting has synergistic activity in AML in vitro and in vivo. (A) 54 primary AML samples were incubated with a 6-log concentration range of Compound 1 (HCl salt), nd 2 or a 1:1 concentration in RPMI/15% FCS for 48h and the LC50 determined (B) Four cohorts of NSG mice were engrafted with luciferase expressing MV4;11 cells. Tumour engraftment was verified on day 10 (baseline) and then Compound 1, HCl 100mg/d orally on ys (expressed as the free base) or Compound 2 25mg/kg IV twice weekly administration commenced for 4 weeks. The impact of Compound 2 and the combination with Compound 1 was evidenced by d luciferase bulk on days 14 and 28 after starting therapy and increased overall al (C).

Figure 3. Toxicity assessment of combined BCL-2/MCL1 targeting on normal CD34+ cells from normal donors or leukaemic blasts. Sorted normal CD34+ or leukaemic blasts were plated and treated with Compound 1, HCl and Compound 2 at 1:1 ratio at the indicated concentrations. Combined Compound 1 + nd 2 is toxic to leukaemic but not normal CD34+ itors.

Figure 4. Cell growth inhibition effect and synergy combination matrices for tion of cell growth (left) and Loewe excess inhibition (right) afforded by Compound 3 in combination with Compound 1, HCl in DB cells (A) and Toledo cells (B). Values in the effect matrix range from 0 (no inhibition) to 100 (total inhibition).

Values in the y matrix represent the extent of growth inhibition in excess of the theoretical additivity calculated based on the single agent activities of Compound 3 and Compound 1, HCl at the concentrations tested. Synergistic effects occurred across a broad range of single agent concentrations.

Figure 5. Anti-tumor effects of Compound 1, HCl, Compound 3 and the combination of Compound 1, HCl + Compound 3 in lymphoma Karpass422 xenograft model in rats.

Figure 6. Body weight changes in animals treated with Compound 1, HCl, Compound 3 and the combination of Compound 1, HCl + Compound 3 in lymphoma Karpass422 aft model in rats.

Figure 7. Anti-tumor effects of Compound 1, HCl, nd 3 and the combination of Compound 1, HCl + Compound 3 in DLBCL Toledo xenograft model in mice.

Figure 8. Body weight changes in animals treated with Compound 1, HCl, nd 3 and the combination of Compound 1, HCl + Compound 3 in DLBCL Toledo xenograft model in mice.

Figure 9. Cell growth inhibition effect and synergy combination matrices for inhibition of cell growth (left) and Loewe excess inhibition (right) ed by nd 3 (MCL1 inhibitor) in combination with Compound 1, HCl (BCL-2 inhibitor) in the AML cell line OCI-AML3 in two independent experiments.

Values in the effect matrix range from 0 (no inhibition) to 100 (total tion). Values in the synergy matrix ent the extent of growth inhibition in excess of the theoretical additivity calculated based on the single agent activities of Compound 3 and Compound 1, HCl at the concentrations tested. Synergistic effects occurred across a broad range of single agent concentrations.

Figure 10. Cell growth tion effect and synergy combination matrices for inhibition of cell growth (left) and Loewe excess inhibition (right) afforded by Compound 3 (MCL1 inhibitor) in ation with Compound 1, HCl (BCL-2 inhibitor) in the NB cell line LAN-6 in two ndent experiments (N1: upper panel; N2: lower panel). Values in the effect matrix range from 0 (no inhibition) to 100 (total inhibition). Values in the synergy matrix represent the extent of growth inhibition in excess of the theoretical vity calculated based on the single agent activities of Compound 3 and Compound 1, HCl at the concentrations tested.

Figure 11. Cell growth inhibition effect and synergy combination matrices for inhibition of cell growth (left) and Loewe excess inhibition ) afforded by Compound 3 (MCL1 inhibitor) in combination with Compound 1, HCl (BCL-2 inhibitor) in the B-ALL cell line NALM-6 in two independent experiments (N1: upper panel; N2: lower panel) Figure 12. Cell growth inhibition effect and synergy combination matrices for inhibition of cell growth (left) and Loewe excess inhibition (right) ed by Com pound 3 (MCL1 inhibitor) in ation with Compound 1, HCl (BCL-2 inhibitor) in the MCL cell line Z-138.

Figure 13. Cell growth inhibition effect and synergy combination es for inhibition of cell growth (left) and Loewe excess inhibition (right) afforded by Compound 3 (MCL1 inhibitor) in combination with ABT-199 (BCL-2 inhibitor) in AML cell line OCI-AML3 in two independent experiments (N1: upper panel; N2: lower panel).

Figure 14. Exemplary cell growth inhibition effect and synergy combination matrices for inhibition of cell growth (left) and Loewe excess inhibition (right) afforded by Compound 3 (MCL1 inhibitor) in combination with Compound 4, HCl (BCL-2 inhibitor) in AML cell lines (ML-2 cells in A and L-3 in B).

Figures 15 (a)-(e). Dose matrices for inhibition (left), Loewe excess inhibition (middle) and growth inhibition afforded by Compound 3 (MCL1 inhibitor) in ation with Compound 1, HCl (BCL-2 inhibitor) in a panel of SCLC cell lines.

Figures 16 ). Anti-tumor effects of Compound 1, HCl, ABT-199, Compound 3 and the combination of Compound 1, HCl or ABT-199 + Compound 3 in Patientderived primary AML model HAMLX5343 in mice.

Figure 17. Heat-map comparison of AML ivity (LC50) to BH3-mimetic monotherapy, or drug combinations (tested in 1:1 ratio), relative to chemotherapy (idarubicin) after 48h exposure. Cell viability of each primary AML samples after 48h in DMSO is shown.

DETAILED DESCRIPTION OF THE INVENTION The invention therefore es in ment E1, a combination comprising (a) a BCL- 2 inhibitor of formula (I): Y A2 R5 (I) Rd Rb wherein: ♦ X and Y represent a carbon atom or a nitrogen atom, it being understood that they may not simultaneously represent two carbons atoms or two nitrogen atoms, ♦ A1 and A2, er with the atoms carrying them, form an optionally substituted, aromatic or non-aromatic heterocycle Het composed of 5, 6 or 7 ring members which may contain, in on to the nitrogen represented by X or by Y, from one to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in on may be substituted by a group representing a hydrogen atom, a linear or branched (C1-C6)alkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C1-C6)alkyl group, or A1 and A2 independently of one another represent a hydrogen atom, a linear or branched (C1-C6)polyhaloalkyl, a linear or ed (C1-C6)alkyl group or a cycloalkyl, ♦ T represents a en atom, a linear or branched (C1-C6)alkyl group ally substituted by from one to three halogen atoms, a group (C1-C4)alkyl-NR1R2, or a group (C1-C4)alkyl-OR6, ♦ R1 and R2 independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group, or R1 and R2 form with the nitrogen atom carrying them a heterocycloalkyl, ♦ R3 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl group, a (C3-C10)cycloalkyl-(C1-C6)alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, it being understood that one or more of the carbon atoms of the ing groups, or of their possible substituents, may be deuterated, ♦ R4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched )alkyl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated, ♦ R5 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group, or a linear or branched (C1-C6)alkoxy group, ♦ R6 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ Ra, Rb, Rc and Rd, each independently of the others, represent R7, a halogen atom, a linear or ed (C1-C6)alkoxy group, a hydroxy group, a linear or branched (C1-C6)polyhaloalkyl group, a trifluoromethoxy group, -NR7R7', nitro, (C0-C6)alkyl-, R7-CO-NH-(C0-C6)alkyl-, NR7R7'-CO-(C0-C6)alkyl-, -CO-(C0-C6)alkyl-O-, R7-SO2-NH-(C0-C6)alkyl-, R7-NH-CO-NH-(C0-C6)alkyl-, R7-O-CO-NH-(C0-C6)alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (Ra,Rb), (Rb,Rc) or (Rc,Rd) form together with the carbon atoms ng them a ring composed of from 5 to 7 ring members, which may contain from one to 2 hetero atoms selected from oxygen and sulphur, it also being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from halogen and linear or branched )alkyl, ♦ R7 and R7' independently of one another represent a en, a linear or branched (C1-C6)alkyl, a linear or branched (C2-C6)alkenyl, a linear or branched (C2-C6)alkynyl, an aryl or a heteroaryl, or R7 and R7' together with nitrogen atom carrying them form a heterocycle composed of from 5 to 7 ring members, it being tood that when the compound of formula (I) contains a hydroxy group, the latter may be optionally converted into one of the following groups: –OPO(OM)(OM’), -OPO(OM)(O-M1+), –OPO(O-M1+)(O-M2+), –OPO(O-)(O-)M32+, –OPO(OM)(O[CH2CH2O]nCH3), or –OPO(O-M1+)(O[CH2CH2O]nCH3), wherein M and M' independently of one another represent a hydrogen atom, a linear or ed (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl or a heterocycloalkyl, both composed of from 5 to 6 ring members, while M1+ and M2+ independently of one another represent a pharmaceutically acceptable monovalent cation, M32+ ents a pharmaceutically acceptable divalent cation, and n is an integer from 1 to 5, it being tood that: - "aryl" means a phenyl, naphthyl, biphenyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens), - "cycloalkyl" means any mono- or lic, non-aromatic, yclic group containing from 3 to 10 ring members, - "heterocycloalkyl" means any mono- or lic, non-aromatic, condensed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO2 and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so d and the groups alkyl, alkenyl, alkynyl and alkoxy to be substituted by from 1 to 3 groups selected from: linear or branched (C1-C6)alkyl optionally substituted by a hydroxyl, a morpholine, 3difluoropiperidine or a 3difluoropyrrolidine; (C3-C6)spiro; linear or branched )alkoxy optionally tuted by a morpholine; (C1-C6)alkyl-S-; hydroxyl; oxo; N-oxide; nitro; cyano; ; -OCOR'; NR'R''; linear or branche d (C1-C6)polyhaloalkyl; trifluoromethoxy; (C1-C6)alkylsulphonyl; n; aryl optionally substituted by one or more halogens; aryl; aryloxy; arylthio; cycloalkyl; heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R' and R'' independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group optionally tuted by a methoxy, it being possible for the Het group defined in formula (I) to be substituted by from one to three groups selected from linear or branched (C1-C6)alkyl, hydroxy, linear or branched (C1-C6)alkoxy, NR1'R1" and halogen, it being understood that R1' and R1" are as defined for the groups R' and R'' mentioned hereinbefore, or its enantiomers, diastereoisomers, or addition salts thereof with a pharmaceutically acceptable acid or base, and (b) a MCL1 inhibitor, for simultaneous, sequential or separate use.

The ion also provides in embodiment E2 a combination comprising (a) a BCL-2 tor and (b) a MCL1 inhibitor of formula (II): wherein: ♦ A ents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched )alkynyl group, a linear or branched )alkoxy group, -S-(C1-C6)alkyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a cyano, -NW10W10’, -Cy6 or an halogen atom, ♦ W1, W2, W3, W4 and W5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a linear or branched (C1-C6)alkoxy group, -S-(C1-C6)alkyl group, a cyano, a nitro group, -alkyl(C0-C6)-NW8W8’, -O-Cy1, -alkyl(C0-C6)-Cy1, -alkenyl(C2-C6)-Cy1, -alkynyl(C2-C6)-Cy1, -O-alkyl(C1-C6)-W9, -C(O)-OW8, -O-C(O)-W8, -C(O)-NW8W8’, -NW8-C(O)-W8’, (O)-OW8’, -alkyl(C1-C6)-NW8-C(O)-W8’, -SO2- NW8W8’, -SO2-alkyl(C1-C6), or the substituents of one of the pairs (W1, W2), (W2, W3), (W1, W3), (W4, W5) when grafted onto two nt carbon atoms, form together with the carbon atoms carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that resulting ring may be substituted by a group selected from a linear or branched (C1-C6)alkyl group, -NW10W10’, -alkyl(C0-C6)-Cy1 or an oxo, ♦ X’ represents a carbon or a nitrogen atom, ♦ W6 represents a hydrogen, a linear or branched (C1-C8)alkyl group, an aryl, an heteroaryl group, an arylalkyl(C1-C6) group, an heteroarylalkyl(C1-C6) group, ♦ W7 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, -alkyl(C1-C6)-Cy3, -alkenyl(C2-C6)-Cy3, -alkynyl(C2-C6)-Cy3, -Cy3-Cy4, -alkynyl(C2-C6)-O-Cy3, -Cy3-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy4, an halogen atom, a cyano, -C(O)-W11, -C(O)-NW11W11’, ♦ W8 and W8’ independently of one another represent a hydrogen atom, a linear or ed (C1-C6)alkyl group, or -alkyl(C0-C6)-Cy1, or (W8, W8’) form together with the en atom carrying them an ic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from one to 3 atoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group enting a hydrogen atom, or a linear or branched (C1-C6)alkyl group and it being understood that one or more of the carbon atoms of the possible substituents, may be deuterated, ♦ W9 represents -Cy1, -Cy1-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)-NW8-alkyl(C0-C6)-Cy2, -Cy1-Cy2-O-alkyl(C0-C6)-Cy5, -C(O)-NW8W8’, -NW8W8’, -OW8,-NW8-C(O)-W8’, -O-alkyl(C1-C6)-OW8, -SO2-W8, -C(O)-OW8, -NH-C(O)-NH-W8, , or , it being possible for the ammonium so defined to exist as a zwitterionic form or to have a lent anionic rion, ♦ W10, W10’, W11 and W11’ independently of one another ent a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ W12 represents a hydrogen or a hydroxy group, ♦ W13 ents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ W14 represents a -O-P(O)(O-)(O-) group, a -O-P(O)(O -)(OW 16) group, a -O-P(O)(OW16)(OW16’) group, a -O- group, a -O-SO2-OW16 group, -Cy7, a -O-C(O)-W15 group, a -O-C(O)-OW15 group or a -O-C(O)-NW15W15’ group, ♦ W15 and W15’ ndently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or a linear or branched amino(C1-C6)alkyl group, ♦ W16 and W16’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or an arylalkyl(C1-C6) group, ♦ Cy1, Cy2, Cy3, Cy4, Cy5, Cy6 and Cy7 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl or an heteroaryl group, ♦ n is an integer equal to 0 or 1, it being understood that: - "aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, - "cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, - “heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring s, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring s, it being possible for the aryl, heteroaryl, cycloalkyl and cycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy, to be substituted by from 1 to 4 groups selected from linear or branched (C1-C6)alkyl which may be tuted by a group representing a linear or branched (C1-C6)alkoxy which may be substituted by a linear or branched )alkoxy, a linear or branched (C1-C6)polyhaloalkyl, hydroxy, halogen, oxo, -NW’W’’, -O-C(O)-W’, or -CO-NW’W’’; linear or branched (C2-C6)alkenyl group; linear or branched (C2-C6)alkynyl group which may be substituted by a group representing a linear or branched )alkoxy; linear or branched (C1-C6)alkoxy which may be substituted by a group representing a linear or branched (C1-C6)alkoxy, a linear or branched )polyhaloalkyl, a linear or branched (C2-C6)alkynyl, -NW’W’’, or hydroxy; (C1-C6)alkyl-S- which may be substituted by a group representing a linear or ed (C1-C6)alkoxy; hydroxy; oxo; N-oxide; nitro; cyano; -C(O)-OW’; -O-C(O)-W’; -CO-NW’W’’; -NW’W’’; - (C=NW’)-OW’’; linear or branched (C1-C6)polyhaloalkyl; trifluoromethoxy; or halogen; it being understood that W’ and W’’ independently of one another represent a en atom or a linear or branched (C1-C6)alkyl group which may be substituted by a group representing a linear or branched (C1-C6)alkoxy; and it being understood that one or more of the carbon atoms of the preceding possible substituents, may be deuterated, its enantiomers, reoisomers or atropisomers, or addition salts thereof with a pharmaceutically acceptable acid or base, for simultaneous, sequential or separate use.

Further enumerated embodiments (E) of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.

E3. A combination according to E1, wherein the MCL1 inhibitor is a nd of formula (II) as defined in E2.

E4. A ation according to any of E1 to E3, wherein the BCL-2 inhibitor is N-(4- hydroxyphenyl){6-[((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl) carbonyl]-1,3-benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide.

E5. A combination according to any of E1 to E3, wherein the BCL-2 inhibitor is 5-(5- {[(3S)(morpholinylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H- pyrrolecarboxamide.

E6. A combination according to E4, wherein N-(4-hydroxyphenyl){6-[((3S)(4- morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}-N- phenyl-5,6,7,8-tetrahydroindolizine carboxamide is in the form of the hydrochloride salt.

E7. A combination according to E5, wherein 5-(5-chloro{[(3S)(morpholin ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl- 1H-pyrrolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrolecarboxamide is in the form of the hydrochloride salt.

E8. A combination ing to E4 or E6, wherein the dose of N-(4-hydroxyphenyl){6- [((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3- benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide during the combination treatment is from 50 mg to 1500 mg.

E9. A combination according to any of E1 to E8, n the BCL-2 inhibitor is administered once a week.

E10. A combination according to E6 or E8, wherein N-(4-hydroxyphenyl){6-[((3S) (4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}- N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide is administered during the combination treatment once a day.

E11. A combination according to any of E1 to E3, wherein the BCL-2 inhibitor is ABT- 199.

E12. A combination according to any of E1 to E11, wherein the MCL1 inhibitor is (2R) {[(5Sa){3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(5- furanyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[1-(2,2,2-trifluoroethyl)-1H- pyrazolyl]methoxy}phenyl)propanoic acid.

E13. A combination according to any of E1 to E11, wherein the MCL1 tor is (2R) {[(5Sa){3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(4- fluorophenyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[2-(2-methoxyphenyl)pyrimidin yl]methoxy}phenyl)propanoic acid.

E14. A combination according to any of E1 to E13, wherein the BCL-2 inhibitor and the MCL1 inhibitor are administered orally.

E15. A combination according to any of E1 to E13, wherein the BCL-2 inhibitor is administered orally and the MCL1 inhibitor is administered enously.

E16. A combination according to any of E1 to E13, wherein the BCL-2 inhibitor and the MCL1 inhibitor are administered intravenously.

E17. A combination according to any of E1 to E16, for use in the treatment of cancer.

E18. The combination for use according to E17, wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in amounts which are jointly therapeutically effective for the treatment of cancer.

E19. The ation for use ing to E17, wherein the BCL-2 tor and the MCL1 inhibitor are provided in amounts which are synergistically effective for the treatment of cancer.

E20. The combination for use according to E17, wherein the BCL-2 tor and the MCL1 inhibitor are ed in synergistically effective amounts which enable a reduction of the dose required for each compound in the treatment of cancer, whilst providing an efficacious cancer treatment, with eventually a reduction in side effects.

E21. The combination for use according to any of E17 to E20, n the cancer is leukaemia.

E22. The combination for use according to E21, wherein the cancer is acute myeloid leukaemia, T-ALL or B-ALL.

E23. The combination for use according to any of E17 to E20, wherein the cancer is myelodysplastic syndrome or myeloproliferative disease.

E24. The combination for use according to any of E17 to E20, wherein the cancer is lymphoma.

E25. The combination for use according to any of E24, wherein the lymphoma is a non- Hodgkin lymphoma.

E26. The combination for use according to any of E25, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma or mantle-cell lymphoma.

E27. The ation for use according to any of E17 to E20, wherein the cancer is multiple myeloma.

E28. The combination for use according to any of E17 to E20, wherein the cancer is neuroblastoma.

E29. The combination for use according to any of E17 to E20, n the cancer is small cell lung .

E30. A combination according to any of E1 to E16, further comprising one or more excipients.

E31. The use of a combination according to any of E1 to E16, in the manufacture of a medicament for the treatment of cancer.

E32. The use according to E31, n the cancer is leukaemia.

E33. The use ing to E32, wherein the cancer is acute myeloid leukaemia, T-ALL or B-ALL.

E34. The use according to E31, n the cancer is myelodysplastic syndrome or roliferative disease.

E35. The use according to E31, wherein the cancer is lymphoma.

E36. The use according to E35, wherein the lymphoma is a non-Hodgkin lymphoma.

E37. The use according to E36, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma or -cell lymphoma.

E38. The use according to E31, wherein the cancer is multiple myeloma.

E39. The use according to E31, wherein the cancer is neuroblastoma.

E40. The use according to E31, wherein the cancer is small cell lung cancer.

E41. A medicament containing, separately or together, (a) a BCL-2 inhibitor of formula (I) as defined in E1, and (b) a MCL1 inhibitor, for simultaneous, sequential or separate administration, and n the BCL-2 inhibitor and the MCL1 inhibitor are provided in effective amounts for the treatment of cancer.

E42. A medicament containing, separately or together, (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of formula (II) as defined in E2, for simultaneous, sequential or separate administration, and wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in effective amounts for the treatment of cancer.

E43. A method of treating , comprising administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor of formula (I) as d in E1, and (b) a MCL1 inhibitor, to a subject in need thereof.

E44. A method of ng cancer, comprising administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of formula (II) as defined in E2, to a subject in need thereof.

E45. A method for sensitizing a patient who is (i) refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with herapy, or both (i) and (ii), n the method comprises administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor of formula (I) as defined in E1, and (b) a MCL1 inhibitor, to said patient.

E46. A method for sensitizing a patient who is (i) refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii), wherein the method comprises administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of formula (II) as defined in E2, to said patient.

“Combination” refers to either a fixed dose combination in one unit dosage form (e.g., capsule, , or sachet), non-fixed dose combination, or a kit of parts for the combined administration where a compound of the present invention and one or more ation partners (e.g. another drug as explained below, also referred to as peutic agent” or “co-agent”) may be administered independently at the same time or tely within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g. synergistic effect.

The terms “co-administration” or “combined administration” or the like as utilized herein are meant to encompass administration of the selected ation partner to a single t in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not arily administered by the same route of administration or at the same time.

The term “fixed dose combination” means that the active ingredients, e.g. a compound of formula (I) and one or more combination partners, are both administered to a patient simultaneously in the form of a single entity or dosage.

The term “non-fixed dose combination” means that the active ients, e.g. a compound of the present invention and one or more combination partners, are both administered to a patient as separate es either simultaneously or sequentially, with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.

“Cancer” means a class of disease in which a group of cells display uncontrolled growth.

Cancer types include ological cancer (lymphoma and leukaemia) and solid tumors including carcinoma, sarcoma, or blastoma. In particular r” refers to leukaemia, lymphoma or multiple myeloma, and more ally to acute myeloid leukaemia.

The term “jointly therapeutically effective” means that the eutic agents may be given separately (in a logically staggered manner, especially a sequence-specific manner) in such time intervals that they prefer, in the warm-blooded animal, especially human, to be d, still show a (preferably synergistic) interaction (joint therapeutic effect).

Whether this is the case can, inter alia, be determined by following the blood levels, showing that both compounds are present in the blood of the human to be treated at least during certain time intervals.

“Synergistically effective” or gy” means that the therapeutic effect observed following administration of two or more agents is greater than the sum of the therapeutic effects observed following the administration of each single agent.

As used herein, the term “treat”, “treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or er (i.e., slowing or ing or reducing the development of the disease or at least one of the al symptoms thereof).

In another ment “treat”, "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, ”, "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.

As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.

In another aspect, provided is a method for sensitizing a human who is (i) refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii), wherein the method comprises administering a BCL-2 inhibitor of formula (I) in combination with a MCL1 inhibitor, as described herein, to the t. A patient who is sensitized is a patient who is sive to the treatment involving administration of a BCL-2 tor of formula (I) in combination with a MCL1 inhibitor, as described herein, or who has not developed resistance to such treatment.

“Medicament” means a pharmaceutical composition, or a ation of several pharmaceutical compositions, which contains one or more active ingredients in the presence of one or more excipients.

‘AML’ means acute d leukaemia.

‘T-ALL’ and ‘B-ALL’ means T-cell acute lymphoblastic leukemia a nd B-cell acute lymphoblastic leukemia. ‘free base’ refers to compound when not in salt form.

In the pharmaceutical compositions according to the invention, the proportion of active ingredients by weight t of active ingredients over the total weight of the composition) is from 5 to 50 %.

Among the pharmaceutical compositions according to the invention there will be more especially used those which are suitable for administration by the oral, parenteral and especially intravenous, per- or trans-cutaneous, nasal, rectal, perlingual, ocular or respiratory route, more ically tablets, s, sublingual tablets, hard gelatin es, glossettes, capsules, lozenges, able preparations, aerosols, eye or nose drops, suppositories, creams, ointments, dermal gels etc.

The pharmaceutical compositions according to the invention comprise one or more excipients or rs selected from diluents, lubricants, binders, disintegration agents, stabilisers, preservatives, ents, colourants, sweeteners, flavourings etc.

By way of non-limiting example there may be mentioned:  as diluents: e, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerol,  as lubricants: silica, talc, stearic acid and its magnesium and m salts, polyethylene glycol,  as binders: magnesium aluminium silicate, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone,  as disintegrants: agar, alginic acid and its sodium salt, effervescent mixtures.

The compounds of the combination may be stered simultaneously or sequentially.

The administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients. The compounds of the ation may moreover be stered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.

Preference is given to the pharmaceutical compositions being tablets.

Pharmaceutical ccoommppoossiittiioonn ooff CCoommppoouunndd 11 HHCCll ssaalltt ffiillmm--ccooaatteedd ttaabblleett ccoonnttaaiinniinngg 5500 mg aanndd 110000 mmgg ooff ddrruugg ssuubbssttaannccee Amount (mg) Function 50 mg Tablet strength 100 mg strength Compound 1 HCl salt 52,58 105,16 Drug Substance lent in base to 50 100 Lactose monohydrate 178,51 357,02 Diluent Maize starch 66,6 133,2 Disintegrant ne 23,31 46,62 Binder Magnesium stearate 3,33 6,66 Lubricant Silica, colloidal anhydrous 0,67 1,34 Flow agent Sodium starch glycolate (Type A) 10 20 Disintegrant For an uncoated tablet with a mass of 335 670 oating Glycerol 0,507 1,014 Plasticizing agent hypromellose 8,419 16,838 Film-coating agent Macrogol 6000 0,538 1,076 Smoothing agent ium stearate 0,507 1,014 Lubricant Titanium dioxide 1,621 3,242 Pigment Intermediary Vehicule Water, purified qs. qs. Solvent For a film-coated tablet with a mass of 346,6 693,2 PHARMACOLOGICAL DATA AL AND METHOD FOR EXAMPLES 1-3: Primary AML t samples: Bone marrow or peripheral blood samples from patients with AML were collected after informed consent in accordance with ines approved by The Alfred Hospital Human research ethics committees. Mononuclear cells were isolated by Ficoll-Paque (GE Healthcare, VIC, Aus) density-gradient centrifugation, followed by red cell depletion in ammonium chloride (NH4Cl) lysis buffer at 37°C for 10 minutes. Cells were then re-suspended in phosphate-buffered saline containing 2% Fetal Bovine serum (Sigma, NSW, Aus). Mononuclear cells were then suspended in 640 (GIBCO VIC, Aus) medium containing penicillin and streptomycin (GIBCO) and heat inactivated fetal bovine serum 15% ).

Cell lines, cell culture and generating luciferase reporter cell lines: Cell lines MV4;11, OCI-AML3, HL-60, HEL, K562, KG-1 and EOL-1 were maintained at 37°C, 5% CO2 in RPMI-1640 (GIBCO) supplemented with 10% (v/v) fetal bovine serum (Sigma) and penicillin and streptomycin (GIBCO). MV4;11 luciferase cell lines were generated by lentivral transductions.

Antibodies: Primary antibodies used for western blot analysis were MCL1, BCL-2, Bax, Bak, Bim, BCL-XL (generated in-house WEHI) and tubulin (T-9026,Sigma).

Cell Viability: Freshly purified mononuclear cells from AML t samples were adjusted to a concentration of 2.5x105/ml and 100μL of cells aliquoted per well into 96 well plates (Sigma). Cells were then treated with Compound 1, HCl, nd 2, ABT- 199 (Active m, NJ, USA) or icin (Sigma), over a 6 log concentration range from 1nM to 10μM for 48hr. For combinations assays, drugs were added at a 1:1 ratio from 1nM to 10uM and incubated at 37°C 5% CO2. Cells were then stained with sytox blue nucleic acid stain (Invitrogen, VIC, Aus) and fluorescence measured by flow cytometric analysis using the LSR-II Fortessa (Becton Dickinson, NSW, Aus). FACSDiva software was used for data collection, and FlowJo software for is. Blast cells were gated using forward and side scatter properties. Viable cells excluding sytox blue were determined at 6 concentrations for each drug and the 50% lethal tration (LC50, in μM) determined.

LC50 determination and synergy: Graphpad Prism was used to calculate the LC50 using non-linear regression. y was determined by calculating the Combination Index (CI) based on the Chou Talalay method as described (Chou Cancer Res; 70(2) January 15, 2010).

Colony : Colony g assays were med on freshly purified and frozen mononuclear fractions from AML patients. Primary cells were cultured in duplicate in 35mm dishes (Griener-bio, Germany) at 1 x 104 to 1 x 105. Cells were plated in 0.6% agar (Difco NSW, Aus): AIMDM 2x (IMDM powder-Invitrogen), mented with NaHCO3, dextran, Pen/Strep, B mercaptoethanol and asparagine):Fetal Bovine Serum (Sigma) at a 2:1:1 ratio. For l growth conditions all plates contained GM-CSF (100ng per plate), IL-3(100ng/plate R&D Systems, USA) SCF(100ng/plate R&D Systems) and EPO (4U/plate) (Growth was for 2-3 weeks in the presence and absence of drug at 37°C at 5% CO2 in a high humidity incubator. After incubation plates were fixed with 2.5% glutaraldehyde in saline and scored using the GelCount from Oxford ix (Abingdon, United Kingdom).

Western Blotting: Lysates were prepared in NP40 lysis buffer (10 mM Tris-HCl pH 7.4, 137 mM NaCl, 10% glycerol, 1% NP40), supplemented with protease inhibitor cocktail (Roche, Dee Why, NSW, Australia). Protein samples were boiled in ng loading dye before separation on 4–12% Bis-Tris polyacrylamide gels (Invitrogen, Mulgrave, VIC, Australia), and transferred to Hybond C nitrocellulose membrane (GE, Rydalmere, NSW, Australia) for tion with specified antibodies. All membrane-blocking steps and antibody dilutions were performed using 5% (v/v) skim milk in PBS containing 0.1% (v/v) Tween-20 phosphate-buffered saline (PBST) or Tris-buffered-saline, and washing steps performed with PBST or TBST. Western blots were visualized by enhanced chemiluminescence (GE).

In vivo experimentation AML engraftment: Animal studies were performed under the institutional guidelines approved by the Alfred Medical Research and Education Precinct Animal Ethics Committee, MV4;11 cells transduced with the luciferase reporter ) were enously injected at 1×105 cells into irradiated (100Rad) non-obese diabetic/severe combined immunodeficient (NOD/SCID/ IL2rγnull) mice as previously described (Jin et al., Cell Stem Cell 2 July 2009, Volume 5, Issue 1, Pages 31–42).

Engraftment was ed at day 7 by quantifying the percentage of hCD45+ cells in the PB by flow cytometry and by IVIS imaging of bioluminescent MV4;11 cells. At day 10, mice received daily oral gavage of nd 1, HCl (200µL 100mg/kg – dosage expressed as the free base) dissolved in PEG400 ), absolute ethanol (Sigma) and led H20 40:10:60 or Compound 2 (200µL 25mg/kg) twice weekly dissolved in 50% 2- hydroxypropyl)-β-cyclodextrin (Sigma) and 50% 50mM HCl or the drug combination or vehicle, over 4 weeks. Blood counts were determined using a hematology er (BioRad, Gladesville, NSW).

IVIS imaging: Bioluminescent imaging was performed using the Caliper IVIS Lumina III XR imaging system. Mice were anaesthetised with isofleurine and injected intraperitoneally with 100µL of 125 mg/kg rin (Perkin Elmer, Springvale, VIC).

MATERIAL AND METHOD FOR EXAMPLE 4: Cell lines: Human myeloma cell lines (HMCLs) were derived from primary myeloma cells ed in RPMI 1640 medium supplemented with 5% fetal calf serum from and 3 ng/mL recombinant IL-6 for IL-6 dependent cell lines. HMCLs are representative of phenotypic and genomic heterogeneity and the variability in patient’s response to therapy.

MTT assay: Cell viability is measured using MTT 5-dimethylthiazolyl)-2,5- diphenyltetrazolium bromide) colorimetric survival assay. Cells are incubated with compounds in 96-well plates containing a final volume of 100 µl/well time. (2R){[(5Sa)- -{3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(5-fluorofuran yl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[1-(2,2,2-trifluoroethyl)-1H-pyrazol yl]methoxy}phenyl)propanoic acid (Compound 2) is used at 9 different concentrations accordingly to single agent ivity. N-(4-hydroxyphenyl){6-[((3S)(4- linylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}-N- phenyl-5,6,7,8-tetrahydroindolizine carboxamide hydrochloride (Compound 1, HCl) is used at a fixed dose – 1 µM. At the end of each treatment, cells are ted with 1 mg/mL MTT (50 µl MTT solution 2.5 mg/ml for each well) at 37°C for 3 hours allowing the MTT to be metabolized. Lysis buffer (100 µl Lysis : DMF (2:3) /SDS (1:3)) is added into each well to dissolve formazan cristals and after 18h of incubation, absorbance in viable cells is measured at 570 nm using a spectrophotometer.

As control, cells are incubated with medium alone and with medium containing 0.1% DMSO. As myeloma cell growth control, myeloma cell absorbance is recorded every day (D0, D1, D2, D3 and D4).

All experiments are repeated 3 times, and each experimental condition is repeated at least in triplicate wells in each experiment.

The inhibition effect is calculated with the following formula: Inhibition effect (%) = (1-Absorbance value of treated cells/Absorbance value of control cells)*100 EXAMPLE 1: BCL-2 and MCL1 are the dominant pro-survival proteins expressed in 7 AML cell lines and 13 primary AML samples with >70% blasts were immunoblotted for proteins indicated in Figure 1.

As illustrated in Figure 1, a proteomic survey of the expression of BCL-2 family members in AML showed that, in addition to BCL-2, most primary AML samples and AML cell lines co-expressed the pro-survival protein MCL1. BCL-XL is less frequently sed in AML.

EXAMPLE 2: Combined BCL-2 and MCL1 targeting displays istic killing in 54 AML patient samples were incubated with a 6-log concentration range of Compound 1 (HCl salt), Compound 2 or a 1:1 concentration in RPMI/15% FCS for 48h and the LC50 ined (Figure 2A).

Approximately 20% of primary AML samples were highly sensitive to either Compound 1 or Compound 2, with the lethal concentration of drug required to kill 50% of primary AML blasts after 48 hours (LC50) in the low nanomolar range (LC50<10nM) e 2A). In contrast, when Compound 1 and Compound 2 were combined, the proportion of AML samples that were sensitive increased dramatically to 70%, indicating synergistic activity when BCL-2 and MCL1 were simultaneously targeted e 2A). Some results are displayed in Figure 17.

To verify the in vivo activity of this approach, luciferase expressing MV4;11 AML cells were engrafted into NSG mice and treated with Compound 1 (HCl salt) or Compound 2 alone, or in combination and tumour burden assessed after 14 and 21 days of y (Figure 2B). At the completion of 28 days of therapy, mice were followed for survival (Figure 2C). These experiments showed that the combination of Compound 1 and Compound 2 was highly effective in vivo, validating the impressive activity ed using y AML cells in vitro.

The data presented in s 2A-2C herein show the synergistic combination activity between Compound 1, HCl and Compound 2 in AML.

EXAMPLE 3: Combined BCL-2 and MCL1 inhibition targets leukaemic, but not normal itor function To assess the toxicity of BCL-2 inhibition combined with MCL1 tion on normal human CD34+ cells or ficolled blasts from patients with AML, clonogenic ial was assessed after 2 weeks exposure to combined therapies. Colonies were grown in agar supplemented with 10% FCS, IL3, SCF, GM-CSF and EPO over 14 days and colonies enumerated with an automated Gelcount® analyser. Assays for primary AML samples were performed in duplicate and averaged. Errors for CD34+ represent mean +/- SD of 2 independent normal donor samples. Results were normalised to the number of colonies counted in DMSO control. Indicated drug concentrations were plated on D1. Notably, Compound 1 + Compound 2 suppressed AML colony forming activity without affecting the function of normal CD34+ colony growth.

Taken altogether, Examples 2 and 3 show that dual pharmacological inhibition of BCL-2 and MCL1 is a novel approach to treating AML without need for additional chemotherapy and with an acceptable therapeutic safety window.

EXAMPLE 4:In vitro evaluation of multiple a cell survival in response to a MCL1 inhibitor as a single agent or in combination with a BCL-2 inhibitor The sensitivity of 27 human multiple myeloma cell lines to nd 1, Compound 2 or to Compound 2 in the presence of 1µM of Compound 1 was analyzed by using MTT cell viability assay. 50% inhibitory concentrations (IC50, in nM) were determined.

The results are displayed in the ing table: nd 1, HCl Compound 2 IC50 of Compound 2 in Cell lines the presence of 1 µM of (IC50 nM) (IC50 nM) Compound 1, HCl (nM) AMO1 8610,3 0,5 0,2 ANBL6 1905,0 79,5 20,8 BCN 0 1111,4 59,3 JIM3 >30000 56,3 25,9 JJN3 2692,0 15,6 2,4 KMM1 23926,3 57,8 8,6 KMS11 10486,7 44,1 3,9 KMS12BM 1393,7 44,1 0,03 L363 7581,3 7,6 3,4 LP1 9770,0 158,2 2,9 MM1S 21407,0 138,5 23,0 NAN1 6659,0 5,7 1,4 NAN3 8241,3 1,5 1,2 NAN6 4074,8 7,1 1,8 NAN8 9096,3 75,4 32,5 NAN9 23157,6 9,7 1,1 NCI-H929 15688,3 2,3 1,0 OPM2 6460,7 9,4 1,2 RPMI8226 3204,0 27,4 3,0 SBN 21273,7 221,1 14,6 U266 >30000 170,1 14,9 XG1 9779,7 5,9 0,2 XG11 7912,0 374,7 8,3 XG2 15297,7 6,4 2,7 XG3 7224,7 6,1 1,3 XG6 8544,3 19,2 0,5 XG7 18121,7 16,3 8,0 Strong synergistic activity was demonstrated when combining Compound 1 and nd 2 in the majority of the cell lines as compared to the compounds alone.

E 5:In vitro effect on eration of combining a MCL1 inhibitor with a BCL-2 inhibitor in a panel of 17 Diffuse Large B-Cell Lymphoma (DLBCL) cell lines Material and Method Cell lines were sourced and maintained in the basic media supplemented with FCS (Fetal Calf Serum) as indicated in Table 1. In addition, all media contained llin (100 IU/ml), omycin (100 µg/ml) and L-glutamine (2 mM). Unless otherwise mentioned, culture media and supplements were from Amimed/Bioconcept (Allschwil, Switzerland).

Cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2 and expanded in T-75 flasks. In all cases cells were thawed from frozen stocks, expanded through ≥1 passage using riate dilutions, counted and assessed for viability using a CASY cell counter (Omni Life Science, Bremen, Germany) prior to plating 25 ul/well at the densities indicated in Table 1 into 384-well plates (Corning). All cell lines were determined to be free of mycoplasma contamination by PCR assay performed at Idexx Radil (Columbia, MO, USA) and misidentification ruled out by assessment of a panel of 48 Small Nucleotide Polymorphisms (SNPs) at Asuragen (Austin, TX, USA) or se.

Stock solutions of compounds were prepared at a concentration of 10 mM in DMSO (Sigma) and stored at -20°C. Where necessary to afford a full dose-response curve, the stock solutions were pre-diluted in DMSO to 1’000-fold the desired start concentration (see Table 2). On the day after cell seeding, eight 2.5-fold serial dilutions of each compound were sed, either individually or in all le permutations in a checkerboard fashion, directly into the cell assay plates using a non-contact 300D Digital Dispenser (TECAN, Männedorf, rland) as outlined in Figure 4. The final tration of DMSO was 0.2% in all wells.

Effects of the single agents as well as their checkerboard combinations on cell viability were assessed after 2 days of incubation at 37 °C/5% CO2 by quantification of cellular ATP levels using CellTiterGlo (Promega, Madison, WI, USA) at 25 μL t/well and n=2 replicate plates per condition. Luminescence was fied on a M1000 urpose platereader (TECAN, Männedorf, Switzerland). The number/viability of cells at time of compound addition was likewise assessed and used to assess the degree of the population doubling time of a particular cell line.

Single agent IC50s were calculated using standard four-parametric curve fitting. Potential synergistic interactions between nd combinations were assessed using the Excess Inhibition 2D matrix according to the Loewe additivity model and are reported as Synergy Score (Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666). All calculations were performed using the Combination Analysis Module in-house software. IC50 are defined as the compound tration at which the CTG signal is reduced to 50% of that measured for the vehicle (DMSO) control.

The retation of the Synergy Score is as follows: SS ~ 0 → Additive SS >1 → Weak Synergy SS >2 → Synergy Table 1. Identity and assay conditions for the 17 e Large B-Cell Lymphoma cell lines used in the combination experiments.

Doubling Cell number Cell line Medium (source) %FCS time (hours) seeded/well DB RPMI (ATCC) 10 31.7 500 DOHH-2 RPMI (DSMZ) 10 25.3 500 HT RPMI (ATCC) 10 34.3 2000 Iscove's JM1 10 22.8 500 MEM*(ATCC) KARPAS-422 RPMI (DSMZ) 10 26.5 500 NU-DHL-1 RPMI (DSMZ) 20 28.0 500 MEM alpha OCI-LY-19 20 25.8 500 (DSMZ) Pfeiffer RPMI (ATCC) 10 46.2 2000 RL RPMI (ATCC) 10 28.9 500 SU-DHL-10 RPMI (DSMZ) 20 105.7 1000 SU-DHL-4 RPMI (DSMZ) 10 25.2 500 -5 RPMI (DSMZ) 20 25.9 500 SU-DHL-6 RPMI (DSMZ) 20 30.1 500 SU-DHL-8 RPMI (DSMZ) 20 23.6 500 Toledo RPMI (ATCC) 10 49.6 2000 U-937 RPMI (ATCC) 10 28.7 500 WSU-DLCL2 RPMI (DSMZ) 10 26.1 500 *This medium was further complemented with 50 µM 2-mercaptoethanol. ng times were calculated based on the difference in ATP levels at the end compared to the beginning of compound incubation.

Table 2. Single agent IC50 values for Compound 3 and Compound 1, HCl, as well as the synergy scores for their ation are indicated. Interactions were deemed synergistic when scores ≥ 2.0 where observed.

Compound 3 Compound 1, HCl Combination Start Abs Max Start Abs Max Synergy Cell Line y conc IC50 Inh conc IC50 Inh Score Score [uM] [uM] [%] [uM] [uM] [%] Error DB 1 0.0129 99.2 10 2.76 95.7 17.3 0.18 DOHH-2 0.1 0.00122 98.3 10 0.156 101.9 2.90 0.11 HT 1 0.00638 99.3 10 ≥10 37.2 2.35 0.06 JM1 1 0.0588 99.7 10 0.697 99.1 5.83 0.25 KARPAS- 1 0.00214 98.3 10 2.18 90.9 9.74 0.32 NU-DHL-1 1 0.0579 98.1 10 0.0515 102.1 4.97 0.12 OCI-LY-19 1 0.0604 98.5 10 0.0895 100.1 3.92 0.07 Pfeiffer 1 0.0426 82.7 10 4.50 92.0 3.44 0.19 RL 10 3.03 95.4 10 0.281 99.0 12.7 0.38 SU-DHL- 1 0.00384 98.3 10 ≥10 43.9 2.44 0.26 SU-DHL-4 1 0.0178 99.5 10 0.86 96.9 10.8 0.28 SU-DHL-5 0.1 0.00094 98.2 10 ≥10 49.6 1.45 0.14 SU-DHL-6 1 0.00213 99.1 10 0.614 101.0 4.57 0.21 SU-DHL-8 10 0.305 95.6 10 ≥10 28.7 9.88 0.20 Toledo 1 ≥1 45.8 10 0.137 101.9 11.1 0.51 U-937 1 0.00832 97.1 10 6.83 62.1 5.63 0.20 1 0.00792 99.0 10 1.02 99.3 8.67 0.13 DLCL2 “Start conc” means start concentration.

“Abs IC50” means absolute IC50.

“Max Inh” means m inhibition.

Results The effect on eration of combining the MCL1 inhibitor Compound 3 with the BCL-2 inhibitor Compound 1, HCl was assessed in a panel of 17 Diffuse Large B-Cell Lymphoma (DLBCL) cell lines.

Compound 3 as single agent strongly inhibited the growth of the majority of the 17 DLBCL lines tested (Table 1). Thus, 14 cell lines displayed IC50s below 100 nM, and an additional 1 cell lines displayed IC50s between 100 nM and 1 uM. Only 2 cell lines displayed an IC50 above 1 uM.

Compound 1, HCl as single agent also inhibited the growth of the majority of the 17 DLBCL lines tested, although slightly less potent (Table 2). Thus, 2 cell lines displayed IC50s below 100 nM, and 6 cell lines displayed IC50s between 100 nM and 1 uM. Nine cell line displayed an IC50 above 1 uM (four of which above 10 uM).

In combination, Compound 3 and Compound 1, HCl treatment caused synergistic growth tion (i.e. Synergy Scores above 2 - Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666) in 16 out of 17 DLBCL cell lines tested (Table 2). In 5 cell lines, the synergy effect was marked, with synergy scores between 5 and 10. In 4 cell lines, the synergy effect was ional, ing synergy scores between 10 and 17.3. Importantly, the synergy was not dependent on single agent anti-proliferative effects, and in fact was particularly strong at concentrations of Compound 3 and Compound 1 that did not display an anti-proliferative effect on their own. For example, in DB cells, nd 3 and Compound 1 at the second lowest concentration tested elicited a growth inhibition of only 1 and 2 %, respectively, while the respective combination of the two compounds afforded a growth tion of 96% (Figure 4A, left panel), thus being 91% above the additivity calculated based on the single agent activities e 4A, right panel). As an additional example, in Toledo cells, in which Compound 3 was less potent and achieved only partial growth inhibition (46%) at the highest concentration tested, the combination with the second lowest concentrations of Compound 1 ed in istic growth inhibition of 98% e 4B, left panel), thus being 52% above the additivity calculated based on the single agent activities (Figure 4B, right panel).

Furthermore, it is noteworthy that the synergistic effects occurred across a broad range of single agent concentrations, which should prove beneficial in vivo with respect to flexibility concerning dosing levels and scheduling.

In summary, the combination of nd 3 and Compound 1 afforded strong to exceptional synergistic growth inhibition in the majority of DLBCL cell lines tested.

EXAMPLE 6: In vivo efficacy in Karpas422 xenografts with ation of a MCL1 inhibitor (Compound 3) and a BCL-2 inhibitor (Compound 1) Material and Method Tumour Cell Culture and Cell Inoculation Karpas 422 human B-cell dgkin's lymphoma (NHL) cell line was established from the pleural effusion of a patient with chemotherapy-resistant NHL. The cells were obtained from the DSMZ cell bank and cultured in RPMI-1640 medium (BioConcept Ltd.

Amimed,) supplemented with 10% FCS (BioConcept Ltd. Amimed), 2 mM L-glutamine (BioConcept Ltd. Amimed), 1 mM sodium pyruvate (BioConcept Ltd. ) and 10 mM HEPES (Gibco) at 37ºC in an atmosphere of 5% CO2 in air. Cells were maintained between 0.5 and 1.5 x 106 cells/mL. To establish Karpas 422 xenografts cells were harvested and re-suspended in HBSS (Gibco) and mixed with Matrigel (BD Bioscience) (1:1 v/v) before injecting 200 µL containing 1x107 cells subcutaneously in the right flanks of animals which were anesthetized with isoflurane. Twenty four hours prior to cell inoculation all animals were irradiated with 5Gy over 2 minutes using a diator.

Tumour Growth Tumour growth was monitored regularly post cell inoculation and animals were randomised into treatment groups (n=5) when tumour volume reached appropriate .

During the treatment period tumour volume was measured about twice a week using calipers. Tumour size, in mm3, was calculated from: (L x W2 x π/6). Where W = width and L = length of the .

Treatment Tumour bearing animals (rats) were enrolled into treatment groups (n=5) when their tumours reached an appropriate size to form a group with a mean tumour volume of about 450 mm3. The ent groups were as outlined in Table 3. The vehicle for Compound 1, HCl or Compound 1, HCl was administered by oral (po) gavage 1 h before vehicle for Compound 3 or Compound 3 which was administered by 15 minutes iv infusion. For iv infusion animals were etized with isoflurane/O2 and the vehicle or Compound 3 administered via a cannula in the tail vein. Animals were weighed at dosing day(s) and dose was body weight adjusted, dosing volume was 10 ml/kg for both compounds.

Body weights Animals were weighed at least 2 times per week and examined frequently for overt signs of any e s.

Data is and statistical evaluation Tumour data were analyzed tically using GraphPad Prism 7.00 (GraphPad Software).

If the variances in the data were normally distributed, the data were analyzed using oneway ANOVA with post hoc Dunnett’s test for comparison of treatment versus control group. The post hoc Tukey’s test was used for intragroup comparison. Otherwise, the Kruskal-Wallis ranked test post hoc Dunn’s was used. When applicable, results are presented as mean ± SEM.

As a measure of efficacy the %T/C value is calculated at the end of the experiment according to: (Δtumour volumetreated/Δtumour control)*100 Tumour regression was calculated according to: -(Δtumour volumetreated/tumour volumetreated at start)*100 wherein Δtumour volumes represent the mean tumour volume on the evaluation day minus the mean tumour volume at the start of the experiment.

Table 3. Treatment groups for combination efficacy in Karpass422 xenograft bearing rats Groups Treatment Dose Number Schedule (expressed as the free base) of rats Vehicle for Compound 1, HCl 0/EtOH/Phosal QW, po 1h 50 PG (30/10/60)), po before 1 10 ml/kg + 10 ml/kg 5 1h before vehicle for + QW, iv Compound 3, 15 infusion minutes iv infusion 10 ml/kg QW, po 1h 5 Vehicle for nd before + 2 0 mg/kg + 20 mg/kg 1, HCl + Compound 3 QW, iv QW, po 1h 5 Compound 1, HCl + before + 3 150 mg/kg + 0 mg/kg Vehicle for Compound 3 QW, iv infusion QW, po 1h 5 Compound 1, HCl + before + 4 150 mg/kg + 20 mg/kg Compound 3 QW, iv infusion ents were initiated when the average tumour volume was about 450 mm3.

Compound 1, HCl was formulated in PEG400/EtOH/Phosal 50 PG (30/10/60) and Compound 3 was placed in solution.

QW means once-weekly.

Results Combination treatment with Compound 1 free base at 150 mg/kg po 1h before Compound 3 at 20 mg/kg iv infusion induces complete regression in all Karpas422 tumours by day 30 from start of treatment (Figure 5). All s in the treatment group have remained tumour free after ent was stopped on day 35 up to day 90. A positive combination effect is observed in the combination group compared with single agent activity. On day 34 the tumour response in the single agent Compound 3 and the combination group are significantly different from the vehicle group (p<0.05).The combination treatment is well tolerated based on body weight changes e 6).

EXAMPLE 7:In vivo efficacy in DLBCL Toledo xenograft with combination of a MCL1 inhibitor (Compound 3) and a BCL-2 inhibitor (Compound 1, HCl) Material and Method Cell implantation The xenograft model was established by direct subcutaneous (sc) implantation of 3 million Toledo cell suspension with 50% matrigel into the subcutaneous area of eige mice.

All procedures were carried out using aseptic technique. The mice were anesthetized during the entire period of the procedure.

In general, a total of 6 s per group were enrolled in efficacy study. For single-agent and combination studies, animals were dosed via oral gavage (po) for Compound 1 and intravenously (iv) via tail vein for nd 3. Compound 1, HCl was formulated as solution in PEG300/EtOH/water (40/10/50), and Compound 3 was placed in solution.

When tumors reached approximately 220 mm3 at day 26 post cell implantation, tumourbearing mice were randomized into treatment groups.

The design of the study ing dose schedule for all treatment groups are summarized in the table below. Animals were weighed at dosing day(s) and dose was body weight ed, dosing volume was 10 ml/kg. Tumour dimensions and body weights were collected at the time of randomization and twice weekly fter for the study duration.

The following data was provided after each day of data collection: incidence of mortality, individual and group average body weights, and individual and group average tumour volume.

Groups Treatment Dose Number of Schedule (expressed as the free base) mice PEG300/EtOH/water 1 e QW, po 6 (40/10/50) 2 Compound 1, HCl 100 mg/kg QW, po 6 3 Compound 3 25 mg/kg QW, iv 6 Compound 1, HCl 100 mg/kg QW, po 6 + Compound 3 25 mg/kg QW, iv For the study in Toledo model, treatments were initiated on day 26 following cell implantation, when the average tumour volume was ~218 to 228 mm3.

QW means once-weekly.

Body Weight (BW) The % change in body weight was calculated as (BWcurrent - BWinitial)/(BWinitial) x 100. Data is presented as percent body weight change from the day of treatment initiation.

Tumour Volume and percent mice remaining on the study Percent treatment/control (T/C) values were calculated using the following formula: % T/C = 100 × ΔT/ΔC if ΔT >0 % Regression = 100 × ΔT/T0 if ΔT <0 where: T = mean tumour volume of the drug-treated group on the final day of the study; ΔT = mean tumour volume of the drug-treated group on the final day of the study – mean tumour volume of the drug-treated group on initial day of dosing; T0 = mean tumour volume of the drug-treated group on the day of cohort; C = mean tumour volume of the control group on the final day of the study; and ΔC = mean tumour volume of the control group on the final day of the study – mean tumour volume of the control group on initial day of dosing.

Percent mice remaining on the study = 6- number of mice ng end point/6*100 Statistical Analysis All data were sed as mean ± rd error of the mean (SEM). Delta tumour volume and percent body weight changes were used for statistical analysis. Between group comparisons were carried out using the One way ANOVA ed by a post hoc Tukey test. For all statistical evaluations, the level of significance was set at p < 0.05.

Significance compared to the vehicle control group is reported unless otherwise stated.

Results Treatment T/C% at day 42 Vehicle 100 Compound 1, HCl 37 Compound 3 102 Compound 1, HCl + Compound 3 In Toledo model, nd 1 free base at 100 mg/kg produced statistically significant anti-tumour effects with 37% T/C. Compound 3 at 25 mg/kg resulted in no anti-tumour effects with 102% T/C (Figure 7). Combination of Compound 1 + Compound 3 led to tumour stasis with 3% T/C, which is statistically significant compared to Vehicle, Compound 1 and Compound 3 treated tumors 5, by one-way ANOVA test).

Therefore, combined inhibition of BCL-2 and MCL1 in DLBCL may provide a therapeutic t in the clinic. In addition, the mean body weight change for Toledo is shown in Figure 8. Treatment of mice with Compound 1, HCl and Compound 3 exhibit body weight gain % and 2.3%, respectively). The combination group showed slight body weight loss (-3.2%). No other signs of adverse events were observed in this study. All 6 animals survived throughout the study.

Taken altogether, Examples 2, 6 and 7 show that the combination of a MCL1 tor and a BCL-2 inhibitor is efficacious at tolerated doses in mice and rats bearing xenografts of acute myeloid leukemia and lymphoma human derived cell lines, suggesting that a suitable therapeutic window is achievable with this ation in these diseases.

EXAMPLE 8:In vitro effect on proliferation of ing a MCL1 inhibitor with a BCL-2 inhibitor in a panel of 13 Acute Myeloid Leukemia (AML) cell lines.

Material and Method Cell lines were sourced and maintained in the basic media supplemented with FBS (Fetal Bovine Serum) as indicated in Table 1. In addition, all media contained penicillin (100 IU/ml), streptomycin (100 µg/ml) and L-glutamine (2 mM).

Cell lines were cultured at 37°C in a fied atmosphere containing 5% CO2 and expanded in T-150 flasks. In all cases cells were thawed from frozen stocks, expanded through ≥1 passage using appropriate dilutions, d and assessed for ity using a CASY cell counter prior to plating 150 ul/well at the densities indicated in Table 1 into 96- well plates. All cell lines were determined to be free of mycoplasma contamination e.

Stock solutions of compounds were prepared at a concentration of 5 mM in DMSO and stored at -20°C.

In order to analyse the ty of the compounds as single agents, cells were seeded and treated with nine 2-fold serial dilutions of each compound dispensed dually directly into the cell assay plates. Effects of the compounds on cell viability were assessed after 3 days of incubation at 37 °C/5% CO2 by quantification of cellular ATP levels using CellTiterGlo at 75 μL reagent/well. All the experiments were med in triplicates. scence was quantified on a multipurpose plate reader. Single agent IC50s were calculated using standard four-parametric curve fitting. IC50 is defined as the compound concentration at which the CTG signal is reduced to 50% of that measured for the vehicle (DMSO) control.

In order to analyse the activity of the compounds in combination, cells were seeded and treated with seven or eight 3.16-fold serial dilutions of each nd dispensed, either individually or in all possible permutations in a checkerboard fashion, directly into the cell assay plates as indicated in Figure 9. Effects of the single agents as well as their rboard combinations on cell viability were assessed after 3 days of incubation at 37 °C/5% CO2 by fication of ar ATP levels using CellTiterGlo at 75 μL reagent/well. Two independent experiments, each one performed in duplicates, were performed. Luminescence was quantified on a multipurpose plate reader.

Potential synergistic interactions between compound combinations were assessed using the Excess Inhibition 2D matrix according to the Loewe additivity model and are reported as Synergy Score (Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666). All calculations were performed using ClaliceTM Bioinformatics Software.

The doubling time ted in Table 3 is the mean of the doubling time obtained in the different passages (in T-150 flasks) performed from the thawing of the cells to their seeding in the 96-weel plates.

The retation of the Synergy Score is as follows: SS ~ 0 → Additive SS >1 → Weak Synergy SS >2 → Synergy Table 3. Identity and assay conditions for the 13 Acute Myeloid Leukemia (AML) cell lines used in the combination experiments.

Medium ng time Cell number Cell line %FBS (source) (hours) seeded/well MV4;11 RPMI (ATCC) 10 31.0 56520 MOLM-13 RPMI (DSMZ) 10 32.4 56520 PL-21 RPMI (DSMZ) 10 32.4 56520 ML-2 RPMI (DSMZ) 10 31.6 56520 Nomo-1 RPMI (DSMZ) 10 43.5 56520 THP-1 RPMI (ATCC) 10 49.6 56520 HL-60 IMDM (ATCC) 20 34.8 56520 Kasumi-1 RPMI (ATCC) 20 59.4 56520 MEM alpha OCI-AML3 20 25.7 56520 (DSMZ) EOL-1 RPMI (DSMZ) 10 37.6 113040 GDM-1 RPMI (ATCC) 10 31.6 56520 KG1 IMDM (ATCC) 20 45.7 56520 KG1a IMDM (ATCC) 20 36.5 56520 Table 4a. Single agent IC50 values for Compound 3, Compound 1, HCl and ABT-199 in 13 AML cell lines are indicated. nds were incubated with the cells during 3 days.

Compound 3 Compound 1, HCl ABT-199 Cell Line Start conc IC50 Start conc IC50 Start conc IC50 [uM] [uM] [uM] [uM] [uM] [uM] MV4;11 0.01 0.001 0.1 0.03 n.d. n.d.

MOLM-13 0.01 0.002 0.1 0.04 n.d. n.d.

PL-21 0.10 0.065 30.0 2.78 15.0 3.300 ML-2 0.10 0.005 2.0 0.04 n.d. n.d.

Nomo-1 0.05 0.013 30.0 7.45 15.0 5.000 THP-1 0.10 0.017 30.0 0.75 2.0 0.900 HL-60 0.10 0.025 30.0 1.42 15.0 2.100 Kasumi-1 2.00 0.033 30.0 0.77 n.d. n.d.

OCI-AML3 2.00 0.146 30.0 8.09 15.0 8.500 EOL-1 0.10 0.001 2.0 0.04 0.2 0.004 GDM-1 0.10 0.008 2.0 0.06 n.d. n.d.

KG1 30.00 0.390 30.0 4.70 15.0 3.400 KG1a 30.00 2.000 30.0 1.75 15.0 0.900 Table 4b. Single agent IC50 values for Compound 4, HCl in 5 AML cell lines are indicated. Compound was incubated with the cells during 3 days.

Compound 4, HCl Cell Line Start conc IC50 [uM] [uM] MV4;11 0.5 0.01 MOLM-13 0.5 0.012 ML-2 0.5 0.01 OCI-AML3 15 5.41 GDM-1 0.5 0.002 Table 5a. Synergy scores for Compound 3 and Compound 1 combination in 13 AML cell lines are indicated. Interactions were deemed synergistic when scores ≥ 2.0 where observed. Start concentrations of compounds, mean of max inhibition and the standard deviation (sd) of the synergy scores are indicated. Compounds were incubated with the cells during 3 days.

Compound 3 nd 1, HCl Combination (a) Start Mean of Mean of Synergy Cell Line Start conc Mean of conc Max Inh Max Inh Score Error [uM] yScore [uM] [%] [%] (sd) MV4;11 0.1 100.0 0.3 99.5 4.3 0.7 MOLM-13 0.1 99.5 0.3 90.0 8.2 1.3 PL-21 0.3 91.5 5.0 75.0 17.9 2.7 ML-2 0.1 99.5 0.3 88.0 10.9 1.8 Nomo-1 0.3 97.0 5.0 31.0 11.8 1.0 THP-1 0.3 99.0 5.0 55.5 13.2 0.1 HL-60 0.3 97.5 5.0 61.5 12.9 1.7 Kasumi-1 0.3 84.5 2.0 52.5 10.5 0.5 OCI-AML3 2.0 100.0 5.0 53.5 19.8 0.2 EOL-1 0.1 100.0 1.0 100.0 5.8 0.8 GDM-1 0.1 99.0 0.3 87.0 11.1 1.4 KG1 2.0 80.5 5.0 53.0 14.6 1.7 KG1a 2.0 28.5 5.0 73.0 13.0 0.9 Table 5b. y scores for Compound 3 and ABT-199 combination in 8 AML cell lines are indicated. Interactions were deemed istic when scores ≥ 2.0 where observed.

Start concentrations of compounds, mean of max inhibition and the standard deviation (sd) of the synergy scores are indicated. Compounds were incubated with the cells during 3 days.

Compound 3 ABT-199 Combination (b) Start Mean of Mean of Synergy Cell Line Start conc Mean of conc Max Inh Max Inh Score Error [uM] SynergyScore [uM] [%] [%] (sd) PL-21 0.3 89.0 2.0 41.5 19.7 2.7 Nomo-1 0.3 95.5 2.0 45.5 10.7 1.6 THP-1 0.3 97.0 0.3 47.0 12.4 0.7 HL-60 0.3 97.5 2.0 56.0 12.9 1.6 OCI-AML3 2.0 100.0 2.0 58.5 16.4 0.5 EOL-1 0.1 100.0 0.1 97.5 4.0 0.3 KG1 2.0 89.0 2.0 54.5 12.2 0.8 KG1a 2.0 57.5 2.0 73.0 17.6 0.1 Table 5c. Synergy scores for Compound 3 and Compound 4, HCl combination in 5 AML cell lines are indicated. Interactions were deemed synergistic when scores ≥ 2.0 where observed. Start concentrations of compounds, mean of max inhibition and the standard deviation (sd) of the synergy scores are indicated. Compounds were incubated with the cells during 3 days.

Compound 3 Compound 4, HCl Combination (c) Start Mean of Start Mean of Synergy Cell Line Mean of conc Max Inh conc Max Inh Score SynergyScore [uM] [%] [uM] [%] Error (sd) MV4;11 0.01 100.0 0.03 70 3.37 0.75 3 0.1 100 0.1 99 3.84 0.02 ML-2 0.1 100 0.1 99 7.09 0.96 OCI-AML3 2.0 100.0 5.0 53.5 16.53 1.62 GDM-1 0.1 100 0.1 99 7.03 0.52 Results Combination (a). The effect on proliferation of combining the MCL1 inhibitor Compound 3 with the BCL-2 inhibitor Compound 1 was assessed in a panel of 13 Acute Myeloid Leukemia (AML) cell lines. nd 3 as single agent strongly inhibited the growth of the majority of the 13 AML lines tested (Table 4a). Thus, 10 cell lines yed IC50s below 100 nM, and an additional 2 cell lines displayed IC50s between 100 nM and 1 uM. Only 1 cell lines displayed an IC50 above 1 uM.

Compound 1, HCl as single agent also inhibited the growth of the several AML lines tested, although slightly less potent (Table 4a). Thus, 5 cell lines displayed IC50s below 100 nM, and 2 cell lines displayed IC50s n 100 nM and 1 uM. Six cell lines displayed an IC50 above 1 uM.

In combination, Compound 3 and nd 1, HCl treatment caused synergistic growth inhibition (i.e. Synergy Scores above 2) in the entire 13 cell lines tested (Table 5a). In 2 cell lines, the synergy effect was marked, with y scores between 5 and 10. In 10 cell lines, the synergy effect was exceptional, ing synergy scores between 10 and 19.8.

Importantly, the synergy was not dependent on single agent anti-proliferative effects, and in fact was particularly strong at concentrations of Compound 3 and nd 1 that did not have an anti-proliferative effect on their own. For example, in OCI-AML3 cells, Compound 3 and Compound 1 at the third lowest concentration tested elicited a growth inhibition of 5 and 1%, respectively, while the tive combination of the two compounds ed a growth inhibition of 84% (Figure 9A, top left panel), thus being 79% above the additivity calculated based on the single agent activities (Figure 9A, top right panel).

Furthermore, it is noteworthy that the synergistic effects occurred across a broad range of single agent concentrations, which should prove beneficial in vivo with respect to flexibility concerning dosing levels and scheduling.

In summary, the combination of Compound 3 and Compound 1 afforded synergistic growth inhibition in all the 13 AML cell lines tested. Importantly, exceptional synergistic growth inhibition was observed in the majority AML cell lines tested (10/13).

Combination (b). The effect on proliferation of combining the MCL1 inhibitor nd 3 with the BCL-2 inhibitor ABT-199 was assessed in a panel of 8 Acute Myeloid Leukemia (AML) cell lines.

Compound 3 as single agent ly inhibited the growth of the majority of the 8 AML lines tested (Table 4a). Thus, 5 cell lines displayed IC50s below 100 nM, and an additional 2 cell lines displayed IC50s between 100 nM and 1 uM. Only 1 cell lines displayed an IC50 above 1 uM.

ABT-199 as single agent also ted the growth of AML lines, although with less potency (Table 4a). Thus, only one cell line displayed IC50s below 100 nM, and 2 cell lines displayed IC50s between 100 nM and 1 uM. Five cell lines displayed IC50 above 1 uM.

In combination, MCL1 inhibitor and ABT-199 treatment caused istic growth inhibition (i.e. Synergy Scores above 2) in the entire panel of 8 cell lines tested (Table 5b).

In the majority of the cell lines, the synergy effect was exceptional, achieving synergy scores between 10 and 17.6. Importantly, the synergy was not dependent on single agent anti-proliferative effects, and in fact was particularly strong at concentrations of MCL1 inhibitor and ABT-199 that did not have an anti-proliferative effect on their own. For example, in L3 cells, MCL1 and ABT-199 at the third lowest concentration tested elicited a growth inhibition of 26% and 18%, respectively, while the respective ation of the two compounds afforded a growth inhibition of 91% (Figure 13, top left panel).

Furthermore, it is noteworthy that the synergistic effects occurred across a broad range of single agent concentrations, which should prove beneficial in vivo with respect to flexibility ning dosing levels and scheduling.

In summary, the combination of nd 3 and ABT-199 afforded synergistic growth tion in all the 8 AML cell lines . Importantly, exceptional synergistic growth inhibition was observed in the majority AML cell lines tested (7/8).

Combination (c). The effect on eration of combining the MCL1 inhibitor Compound 3 with the BCL-2 inhibitor Compound 4 was assessed in a panel of 5 Acute Myeloid Leukemia (AML) cell lines.

Compound 3 as single agent ly inhibited the growth of the 5 AML lines tested (Table 4b). Thus, all cell lines displayed IC50s below 200 nM. Compound 4, HCl as single agent also inhibited the growth of the 4 out of 5 cell lines tested with IC50 below or equal to 40 nM, one cell line being resistant to Compound 4 with an IC50 of 10µM. In combination, Compound 3 and Compound 4, HCl treatment caused synergistic growth inhibition (i.e.

Synergy Scores above 2) in the entire 5 cell lines tested (Table 5c). In 2 cell lines, the y effect was , with synergy scores between 5 and 10. In 1 cell line, the synergy effect was exceptional, achieving synergy score of 16.5. Importantly, the synergy was not dependent on single agent anti-proliferative effects, and in fact was particularly strong at concentrations of Compound 4, HCl and Compound 3 that have no or low antiproliferative effect on their own. For example, in L3 cells, Compound 4, HCl and Compound 3 at the third lowest concentration tested elicited a growth inhibition of 1 and 40%, respectively, while the respective combination of the two compounds afforded a growth inhibition of 98% (Figure 1A, left panel; representative of two independent experiments), thus being 53% above the additivity calculated based on the single agent activities (Figure 14A, right panel). In ML-2, Compound 4, HCl and Compound 3 at the fifth lowest concentration tested ed a growth inhibition of 18 and 26%, respectively, while the respective combination of the two compounds afforded a growth inhibition of 100% (Figure 14B, left panel; representative of two independent experiments), thus being 51% above the additivity calculated based on the single agent activities (Figure 15, right panel) In summary, the ation of Compound 4 and Compound 3 afforded synergistic growth inhibition in all the 5 AML cell lines tested.

E 9:In vitro effect on proliferation of combining a MCL1 inhibitor with a BCL-2 inhibitor in a panel of of 12 neuroblastoma (NB) cell lines Materials and methods Cell lines were sourced and maintained in the basic media supplemented with FBS as indicated in Table 1. In addition, all media contained penicillin (100 IU/ml), streptomycin (100 µg/ml) and L-glutamine (2 mM). Cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2 and expanded in T-150 flasks. In all cases cells were thawed from frozen stocks, expanded through ≥1 e using appropriate dilutions, counted and ed for viability using a CASY cell counter prior to plating 150 ul/well at the ies ted in Table 6 into 96-well plates. All cell lines were determined to be free of mycoplasma contamination in-house.

Stock solutions of compounds were prepared at a concentration of 5 mM in DMSO and stored at -20°C. In order to analyse the activity of the compounds as single , cells were seeded and treated with nine 3.16-fold serial dilutions of each compound dispensed dually directly into the cell assay plates. Effects of the compounds on cell viability were assessed after 2 or 3 days of incubation (as indicated in Table 6) at 37 °C/5% CO2 by quantification of cellular ATP levels using CellTiterGlo at 150 μL reagent/well. Two independent experiments, each one performed in ates were performed. All the experiments were performed in cates. Luminescence was quantified on a multipurpose eader. Single agent IC50s were calculated using standard four-parametric curve fitting. IC50 is defined as the compound concentration at which the CTG signal is reduced to 50% of that measured for the vehicle (DMSO) control.

Identical experiments were performed to assess potential synergistic interactions between compound combinations. Synergy Score were assessed using the Excess Inhibition 2D matrix according to the Loewe additivity model (Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666). All calculations were performed using Chalice TM Bioinformatics Software.

The doubling time indicated in Table 6 is the mean of the doubling time obtained in the different passages (in T-150 flasks) performed from the thawing of the cells to their seeding in the 96-weel plates.

The interpretation of the Synergy Score is as follows: SS ~ 0 → Additive SS >1 → Weak Synergy SS >2 → Synergy Table 6. Identity and assay ions for the 12 neuroblastoma (NB) cell lines used in the combination experiments.

Doubling Cell Days of Cell line Medium (source) %FBS time number tion ) seeded/well with cpds SK-N-AS DMEM (ATCC) 10 33 9375 3 SK-N-BE EMEM/Ham F12 (ATCC) 10 50 37500 3 SK-N-DZ DMEM (ATCC) 10 42 37500 3 LAN-6 DMEM (DSMZ) 20 100 9375 3 NBL-S Iscove's MDM (DSMZ) 10 46 18750 3 SIMA RPMI (DSMZ) 10 60 18750 3 KELLY RPMI (ECACC) 10 34 3750 2 IMR-32 EMEM (ATCC) 10 55 28125 2 1/2 EMEM no in + 1/2 SH-SY-5Y Ham F12 + 2mM Glutamin + 15 35 3750 2 NEAA (ECACC) SK-N-SH EMEM (ATCC) 10 65 3750 2 NB-1 RPMI (JCRB) 10 35 15000 2 SK-N-FI DMEM (ATCC) 10 60 7500 2 Table 7. Single agent IC50 values for Compound 3 and Compound 1, HCl, are indicated.

Compounds were incubated with the cells during 2 or 3 days. nd 3 Compound 1, HCl Cell Line IC50 [uM] IC50 [uM] S 0.26 > 1 E >2 >2 SK-N-DZ >2 >2 LAN-6 >2 >2 NBL-S >2 >2 SIMA >2 >2 NB1 0.123 >3 SK-N-SH >3 >3 SH-SY5Y >3 >3 Kelly 0.031 >3 SK-N-FI >3 >3 Table 8. Synergy scores for combination with Compound 3 and Compound 1, HCl are indicated. Interactions were deemed synergistic when scores ≥ 2.0 where observed.

Compounds were incubated with the cells during 2 or 3 days.

Compound 3 Compound 1, HCl Combination Cell Line Start conc Mean of Max Start conc Max Inh Synergy Score Synergy Score [uM] Inh [%] [uM] [%] Error SK-N-AS 2 84 1 9 2.78 0.46 SK-N-BE 2 27 2 27 10.72 0.78 SK-N-DZ 2 2.5 2 10 0.34 0.06 LAN-6 2 17.5 2 26 10.51 0.39 NBL-S 2 13 2 10 17.81 3.7 SIMA 2 0 2 48.5 2.41 0.75 NB1 3 99 3 11 10.72 4.33 SK-N-SH 3 40 3 15 4.07 0.23 SH-SY5Y 3 24 3 10 10.21 0.54 Kelly 3 99 3 27 9.62 0.48 SK-N-FI 3 33 3 6 4.35 0.91 Results The effect on proliferation of combining the MCL1 inhibitor Compound 3 with the BCL-2 inhibitor Compound 1 was assessed in a panel of 12 neuroblastoma cell lines. Three out of the 12 cell lines tested are sensitive to Compound 3 as single agent (Table 7). One cell lines displayed IC50s below 100 nM, and an additional 2 cell lines displayed IC50s between 100 nM and 1 uM.

All cell lines are resistant to Compound 1, HCl as single agent with all cell lines tested displaying an IC50 above 1µM. In combination, Compound 3 and Compound 1 treatment caused synergistic growth inhibition (i.e. Synergy Scores above 2 - Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666) in 11 out of 12 NB cell lines tested (Table 8). In 5 cell lines, the synergy effect was exceptional, achieving synergy scores between 10 and 17.81. Importantly, the synergy was not dependent on single agent anti-proliferative effects, and in fact was particularly strong at trations of Compound 3 and Compound 1, HCl that did not have an roliferative effect on their own. For example, in LAN-6 cells, Compound 3 and nd 1, HCl at 630 nM ed a growth inhibition of only 12% and 0%, respectively, while the respective ation of the two compounds afforded a growth tion of 95% (Figure 10, upper left panel), thus being 76% above the additivity calculated based on the single agent activities (Figure 10, upper right panel).

In summary, the combination of Compound 3 and nd 1 afforded strong to ional synergistic growth inhibition in the majority of neuroblastoma cell lines tested.

EXAMPLE 10: In vitro effect on proliferation of combining a MCL1 inhibitor with a BCL-2 inhibitor in a panel of 8 B-cell acute lymphoblastic leukaemia (B-ALL) and 10 T-cell acute lymphoblastic leukaemia (T-ALL) cell lines.

Materials and methods Cell lines were sourced and maintained in the basic media supplemented with FBS as indicated in Table 1. In addition, all media contained penicillin (100 IU/ml), streptomycin (100 µg/ml) and L-glutamine (2 mM). Cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2 and expanded in T-150 flasks. In all cases cells were thawed from frozen stocks, expanded through ≥1 e using appropriate dilutions, d and assessed for viability using a CASY cell r prior to plating 150 ul/well at the densities indicated in Table 9 into 96-well plates. All cell lines were determined to be free of mycoplasma contamination se.

Stock solutions of compounds were prepared at a concentration of 5 mM in DMSO and stored at -20°C. In order to analyse the activity of the compounds as single , cells were seeded and treated with nine 2-fold serial dilutions of each compound dispensed individually directly into the cell assay plates. Effects of the compounds on cell viability were assessed after 3 days of incubation at 37 °C/5% CO2 by quantification of ar ATP levels using CellTiterGlo at 75 μL reagent/well. All the conditions were tested in cates. scence was quantified on a multipurpose plate reader. Single agent IC50s were calculated using rd four-parametric curve fitting. IC50 is defined as the compound tration at which the CTG signal is reduced to 50% of that measured for the vehicle (DMSO) control.

In order to analyse the activity of the compounds in combination, cells were seeded and d with seven or eight 3.16-fold serial dilutions of each compound dispensed, either individually or in all possible permutations in a checkerboard fashion, directly into the cell assay plates as ted in Figure 1. Effects of the single agents as well as their checkerboard combinations on cell viability were assessed after 3 days of incubation at 37 °C/5% CO2 by quantification of ar ATP levels using CellTiterGlo at 75 μL reagent/well. For B-ALL cell lines, two independent experiments, each one performed in duplicates, were performed. For T-ALL cell lines, one experiment med in triplicate was performed. Luminescence was quantified on a multipurpose plate reader.

Potential synergistic interactions between compound combinations were assessed using the Excess Inhibition 2D matrix according to the Loewe additivity model and are reported as Synergy Score (Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666). All calculations were performed using Chalice TM Bioinformatics Software available in Horizon website.

The doubling time indicated in Table 9 is the mean of the doubling time obtained in the different passages (in T-150 flasks) performed from the thawing of the cells to their g in the 96-weel plates.

The interpretation of the Synergy Score is as follows: SS ~ 0 → Additive SS >1 → Weak Synergy SS >2 → Synergy Table 9. Identity and assay ions for the 8 B-ALL and 10 T-ALL cell lines used in the combination experiments.

Doubling Cell number Cell line Cancer type Medium (source) %FBS time seeded/well (hours) TOM-1 B-ALL RPMI (DSMZ) 20 70.0 112500 SUP-B15 B-ALL McCoy (DSMZ) 20 35.0 112500 NALM-21 B-ALL RPMI (DSMZ) 10 50.0 112500 NALM-6 B-ALL RPMI (DSMZ) 10 27.0 56250 TANOUE B-ALL RPMI (DSMZ) 10 26.0 30000 Kasumi-2 B-ALL RPMI (DSMZ) 10 52.0 112500 RS4;11 B-ALL RPMI (ATCC) 10 42.0 90000 BALL-1 B-ALL RPMI (DSMZ) 10 38.0 112500 BE-13 T-ALL RPMI 1640 (DSMZ) 10 37.0 13875 MOLT-4 T-ALL RPMI 1640 (ATCC) 10 24.0 28125 TALL-104 T-ALL IMDM (ATCC) 20 68.0 13875 HPB-ALL T-ALL RPMI 1640 (DSMZ) 20 42.0 56250 DND-41 T-ALL RPMI 1640 (DSMZ) 10 38.0 56250 CML-T1 T-ALL RPMI 1640 (DSMZ) 10 32.0 112500 J45.01 T-ALL RPMI 1640 (ATCC) 10 25.0 56250 RPMI 1640 (ATCC) 10 24.0 56250 J.RT3 T3.5 T-ALL RPMI 1640 (ATCC) 10 24.0 56250 Loucy T-ALL RPMI 1640 (ATCC) 10 61.0 112500 Table 10. Single agent IC50 values for Compound 3 and Compound 1, HCl in the 8 B-ALL and 10 T-ALL cell lines are indicated. Compounds were incubated with the cells during 3 days.

Compound 3 Compound 1, HCl Cancer Treatment Cell Line type duration(h) Start conc Start conc IC50 [uM] IC50 [uM] [uM] [uM] TOM-1 B-ALL 72 0.10 0.024 0.15 0.019 SUP-B15 B-ALL 72 2.00 0.078 0.90 0.025 NALM-21 B-ALL 72 0.10 0.012 0.50 0.095 NALM-6 B-ALL 72 2.00 0.120 30.00 3.630 TANOUE B-ALL 72 30.00 6.540 30.00 17.000 -2 B-ALL 72 2.00 0.030 2.00 0.209 RS4;11 B-ALL 72 0.90 0.079 9.00 0.020 BALL-1 B-ALL 72 0.25 0.063 0.10 0.019 BE-13 T-ALL 72 0.15 0.015 30.00 6.700 MOLT-4 T-ALL 72 2.00 0.026 30.00 3.290 TALL-104 T-ALL 72 2.00 0.044 30.00 15.900 HPB-ALL T-ALL 72 2.00 0.660 30.00 4.500 DND-41 T-ALL 72 30.00 7.000 30.00 9.000 CML-T1 T-ALL 72 30.00 6.000 30.00 15.000 J45.01 T-ALL 48 0.60 0.029 30.00 9.000 EM T-ALL 48 0.90 0.047 30.00 7.500 J.RT3 T3.5 T-ALL 48 1.88 0.063 30.00 10.000 Loucy T-ALL 48 0.90 0.064 3.75 0.231 Table 11. Synergy scores for Compound 3 and Compound 1, HCl combination in 8 B- ALL and 10 T-ALL cell lines are indicated. Interactions were deemed synergistic when scores ≥ 2.0 where observed. Start concentrations of compounds, mean of max inhibition and the standard deviation (sd) of the synergy scores are indicated. Compounds were incubated with the cells during 3 days.

Compound 3 Compound 1, HCl Combination Treatment Cancer Cell Line duration Start Mean of Start Mean of Mean of Synergy (h) conc Max conc Max Inh Synergy Score [uM] Inh [%] [uM] [%] Score Error (sd) TOM-1 B-ALL 72 0.3 98.5 0.1 90.5 4.1 0.4 B-ALL 72 2.0 99.0 0.3 97.0 5.6 0.4 NALM-21 B-ALL 72 0.3 99.0 0.3 84.5 9.6 0.0 NALM-6 B-ALL 72 2.0 71.5 5.0 56.5 15.9 1.4 TANOUE B-ALL 72 5.0 78.5 5.0 13.0 1.0 0.6 Kasumi-2 B-ALL 72 0.3 99.0 2.0 82.0 10.1 1.9 RS4;11 B-ALL 72 0.3 87.5 0.3 98.0 7.0 1.3 BALL-1 B-ALL 72 0.3 96.0 0.3 100.0 6.3 0.3 BE-13 T-ALL 72 1.0 95.0 5.0 0.0 8.8 0.4 MOLT-4 T-ALL 72 1.0 99.0 5.0 63.0 4.4 0.1 TALL-104 T-ALL 72 1.0 99.0 2.0 29.0 15.1 0.5 HPB-ALL T-ALL 72 1.0 49.0 5.0 15.0 5.6 0.3 DND-41 T-ALL 72 2.0 17.0 5.0 24.0 10.3 0.3 CML-T1 T-ALL 72 2.0 22.3 5.0 17.0 3.3 0.2 J45.01 T-ALL 48 2.0 100.0 2.0 23.0 2.9 0.1 CCRFT-ALL 48 2.0 92.0 2.0 55.0 4.1 1.0 J.RT3 T3.5 T-ALL 48 2.0 99.0 2.0 32.0 3.8 0.1 Loucy T-ALL 48 2.0 100.0 2.0 77.0 11.3 0.6 Results The effect on proliferation of combining the MCL1 tor with the BCL-2 inhibitor was assessed in a panel of 8 B-ALL and 10 T-ALL cell lines.

MCL1 inhibitor as single agent strongly inhibited the growth of the majority of the ALL cell lines tested (Table 10). Thus, 13 ALL cell lines displayed IC50s below 100 nM, and an additional 2 ALL cell lines displayed IC50s between 100 nM and 1 uM. Only 3 ALL cell lines displayed IC50 above 1 uM.

BCL-2 inhibitor as single agent also inhibited the growth of several ALL cell lines , although it was less potent (Table 10). Thus, 5 cell lines displayed IC50s below 100 nM, and 2 cell lines displayed IC50s between 100 nM and 1 uM. Eleven ALL cell lines displayed an IC50 above 1 uM.

In combination, MCL1 inhibitor and BCL-2 inhibitor treatment caused synergistic growth inhibition (i.e. Synergy Scores above 2 - Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666) in the entire 17/18 ALL cell lines tested (Table 11). In 6 cell lines, the synergy effect was marked, with synergy scores between 5 and 10. In 5 cell lines, the synergy effect was exceptional, achieving y scores between 10 and 15.9. Importantly, the synergy was not dependent on single agent anti-proliferative effects, and in fact was particularly strong at concentrations of MCL1 tor and BCL-2 inhibitor that did not have an roliferative effect on their own. For example, in NALM-6 cells, MCL1 inhibitor and BCL-2 inhibitor at the fourth lowest concentration tested elicited a growth inhibition of 6 and 8%, respectively, while the respective combination of the two compounds afforded a growth inhibition of 61% (Figure 11, top left panel).

Furthermore, it is rthy that the synergistic effects occurred across a broad range of single agent concentrations, which should prove cial in vivo with respect to flexibility concerning dosing levels and scheduling.

In summary, the combination of MCL1 inhibitor and BCL-2 inhibitor afforded synergistic growth inhibition in the majority (17/18) of ALL cell lines tested. Importantly, exceptional synergistic growth inhibition was observed in 5/18 ALL cell lines tested.

EXAMPLE 11: In vitro effect on proliferation of combining a MCL1 inhibitor with a BCL-2 inhibitor in a panel of 5 Mantle Cell Lymphoma (MCL) cell lines. als and methods Cell lines were sourced and maintained in the basic media supplemented with FBS as indicated in Table 12. In on, all media contained penicillin (100 IU/ml), omycin (100 µg/ml) and L-glutamine (2 mM).

Cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2 and expanded in T-150 flasks. In all cases cells were thawed from frozen stocks, expanded through ≥1 passage using appropriate dilutions, counted and assessed for viability using a CASY cell counter prior to plating 150 ul/well at the densities indicated in Table 12 into 96-well . All cell lines were determined to be free of mycoplasma contamination in- house.

Stock solutions of compounds were ed at a concentration of 5 mM in DMSO and stored at -20°C. In order to analyse the activity of the compounds as single agents or in combination, cells were seeded and treated with seven or eight 3.16-fold serial dilutions of each compound dispensed, either individually or in all le ations in a checkerboard fashion, directly into the cell assay plates. Effects of the single agents as well as their checkerboard combinations on cell ity were assessed after 2 days of incubation at 37 °C/5% CO2 by quantification of cellular ATP levels using terGlo at 150 μL reagent/well. All the conditions were tested in triplicates. scence was quantified on a multipurpose plate reader.

Potential istic interactions between compound combinations were assessed using the Excess Inhibition 2D matrix according to the Loewe additivity model and are reported as Synergy Score (Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666). All calculations were performed using ChaliceTM Bioinformatics Software available in Horizon website.

Single agent IC50s were calculated using standard four-parametric curve fitting. IC50 is defined as the compound concentration at which the CTG signal is d to 50% of that measured for the vehicle (DMSO) control.

The doubling time indicated in Table 12 is the mean of the doubling time obtained in the different passages (in T-150 flasks) performed from the thawing of the cells to their seeding in the 96-weel plates.

Synergy Score SS ~ 0 → Additive SS >1 → Weak y SS >2 → Synergy Table 12. Identity and assay conditions for the 5 Mantle Cell Lymphoma cell lines used in the combination experiments.

Doubling Cell number Cell line Medium %FBS Source time /well (hours) Z-138 RPMI 10 ATCC 22.5 37500 Jeko RPMI 20 ATCC 26.0 27000 Mino RPMI 15 ATCC 31.1 56250 JVM-2 RPMI 10 ATCC 76.0 56250 REC-1 RPMI 10 ATCC 36.0 56250 Table 13. Single agent IC50 values for Compound 3 and Compound 1, HCl in the 5 Mantle Cell Lymphoma cell lines are indicated. Compounds were incubated with the cells during 2 days.

Compound 3 Compound 1, HCl Cell Line Start conc Start conc IC50 [uM] IC50 [uM] [uM] [uM] Z-138 2 0.448 5 > 5 Jeko 2 0.023 5 > 5 Mino 2 0.008 2 0.091 JVM-2 2 >2 5 > 5 REC-1 2 0.077 2 0.703 Table 14. Synergy scores for Compound 3 and Compound 1, HCl combination in 5 Mantle Cell Lymphoma cell lines are indicated. Interactions were deemed synergistic when scores ≥ 2.0 where observed. Start concentrations of compounds, max inhibition and the synergy scores are indicated. Compounds were incubated with the cells during 2 days.

Compound 3 Compound 1, HCl Combination Cell Line Start conc Max Inh Start conc Max Inh Synergy Score [uM] [%] [uM] [%] Z-138 2.0 96.0 5.0 25.0 11.1 Jeko 2.0 100.0 5.0 35.0 9.7 Mino 2.0 100.0 2.0 91.0 5.7 JVM-2 2.0 19.0 5.0 38.0 3.4 REC-1 2.0 99.0 2.0 78.0 5.1 Results The effect on proliferation of combining the MCL1 inhibitor with the BCL-2 inhibitor was assessed in a panel of 5 Mantle Cell Lymphoma cell lines.

As single agents, MCL1 inhibitors displayed or activity as ed with BCL-2 inhibitor. Thus, 3 cell lines displayed IC50s below 100 nM for MCL1 inhibitor while only one cell line displayed IC50s below 100 nM for BCL-2 tor (Table 13).

In combination, MCL1 inhibitor and BCL-2 inhibitor treatment caused synergistic growth inhibition (i.e. y Scores above 2 - Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666) in all cell lines tested (Table 14), as examplified in Figure 12. Importantly, in 4/5 cell lines, the synergy effect was marked, with synergy scores above 5.

E 12: In vitro effect on proliferation of combining a MCL1 inhibitor with a BCL-2 inhibitor in a panel of 5 Small Cell Lung Cancer (SCLC) cell lines.

All cell lines were obtained from ATCC. Culture media containin g RPMI1640 (Invitrogen) mented with 10% FBS (HyClone) was used for COR-L95, 46, NCI-H211, SHP-77, SW1271, NCI-H1339, NCI-H1963, and NCI-H889. Culture media containing Waymouth’s MB 752/1 (Invitrogen) with 10% FBS was used for DMS-273. Culture media containing DMEM/F12 (Invitrogen) containing 5% FBS, and supplemented with 0.005 mg/ml insulin, 0.01 mg/ml errin, and 30 nM sodium selenite solution (Invitrogen), 10 nM hydrocortisone (Sigma), 10 nM beta-estradiol (Sigma), and 2 mM L-glutamine (HyClone) was used for 105.

Cell lines were cultured in 37°C and 5% CO2 incubator and expanded in T-75 flasks. In all cases cells were thawed from frozen stocks, expanded through ≥1 passage using 1:3 dilutions, counted and assessed for viability using a ViCell counter (Beckman-Coulter), prior to plating in 384-well. To split and expand cell lines, cells were dislodged from flasks using 0.25% Trypsin-EDTA (GIBCO). All cell lines were determined to be free of mycoplasma contamination as determined by a PCR detection methodology performed at Idexx Radil (Columbia, MO, USA) and tly identified by ion of a panel of SNPs.

Cell eration was measured in 72hr CellTiter-Glo™ (CTG) assays (Promega G7571) and all s shown are the result of at least triplicate ements. For CellTiter-Glo™ assays, cells were dispensed into tissue culture treated ll plates ng 3707) with a final volume of 35 μL of medium and at density of 5000 cells per well. 24 hrs after plating, 5 μL of each compound dilution series were transferred to plates containing the cells, resulting in compound concentration ranges from 0-10 uM and a final DMSO (Sigma D8418) concentration of 0.16%. Plates were incubated for 72 hrs and the effects of compounds on cell proliferation was ined using the CellTiter-Glo™ Luminescent Cell Viability Assay (Promega G7571) and a Envision plate reader (Perkin Elmer).

The CellTiter-Glo® Luminescent Cell Viability Assay is a homogeneous method to determine the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. The method is described in detail in the Technical Bulletin, TB288 Promega. y, cells were plated in Opaque-walled multiwell plates in culture medium as described above. l wells containing medium without cells were also prepared to obtain a value for background luminescence. 15 uL of CellTiter-Glo® Reagent was then added and contents mixed for 10 minutes on an orbital shaker to induce cell lysis. Next, luminescence was recorded using the plate reader.

The percent growth inhibition and excess inhibition were analysed using the Chalice software (CombinatoRx, Cambridge MA). The percentage of growth inhibition relative to DMSO is displayed in the panel labelled inhibition, and the amount of inhibition in excess of the expected amount in the panel labelled ADD Excess Inhibition (Figures 15 (a)-(e)).

Concentrations of Compound 1, HCl are shown along the bottom row from left to right and increasing concentrations of Compound 3 along the leftmost column from bottom to top.

All remaining points in the grids display s from a combination of the two tors that correspond to the single agent concentrations d on the two axes. Data analysis of cell proliferation was med using e Analyser as described in Lehar et al, Nat Biotechnol. 2009 July ; 27(7): 659–666. Excess inhibition was calculated using the Loewe synergy model which measures the effect on growth relative to what would be expected if two drugs behave in a dose ve manner. Positive numbers represent areas of increasing synergy.

Synergy Score SS ~ 0 → Dose Additive SS >2 → Synergy SS >1 → Weak Synergy Results In combination, Compound 1 and Compound 3 treatment caused synergistic growth inhibition (i.e. Synergy Scores above 2) in 8/10 small cell lung cancer cell lines.

Importantly, in 6 cell lines, the synergy effect was marked, with y scores above 6.

EXAMPLE 13: In vivo cy in Patient-derived primary AML model HAMLX5343 with combination of a MCL1 inhibitor (Compound 3) and a BCL-2 inhibitor (Compound 1, HCl or ABT-199) Materials and Methods Materials Animals NOD scid gamma (NSG) female mice weighing 17-27 grams (Jackson Laboratories) were allowed to acclimate with access to food and water ad libitum for 3 days prior to manipulation.

Primary tumor models Patient-derived primary AML model HAMLX5343 carrying KRAS on and wild type FLT3 were obtained from Dana Farber Cancer Institute.

Test compounds, formulations Compound 1, HCl was ated in 5% Ethanol, 20% Dexolve-7 as a solution for intravenous administration or formulated in PEG300/EtOH/water (40/10/50) for oral administration. ABT-199 was formulated in PEG300/EtOH/water (40/10/50) for oral stration. All of them are stable for at least one week at 4oC. Compound 3 was formulated in Liposomal formulation as a solution for enous formulation, which is stable for three weeks at 4oC. Vehicle and compound dosing solutions were prepared as needed. All animals were dosed at 10 mL/kg with Compound 1 (expressed as the free base) or ABT-199, or 5 mL/kg with Compound 3.

Methods Study design Eight treatment groups were used in study MLX5343-XEF as summarized in Table 15. All treatments were initiated when the average tumor burden (%CD-45 positive cells) was between 8% and 15%.

In this study, Compound 1 was stered by oral gavage (po) or intravenous administration at 50 mg/kg once a week, ABT-199 was administered at 25mg/kg by oral gavage (po) once a week, either as a single agent or in combination with Compound 3 at 12.5mg/kg once a week, respectively, for 18 days.

Both Compound 1 (expressed as the free base) and ABT-199 were administered at 10 mL/kg. Compound 3 was administered at 5 mL/kg. The dose was body weight adjusted.

Bodyweights were recorded twice/week and tumor burden was recorded eek.

Table 15. Doses* and dose les for 7844HAMLX5343-XEF Treatment groups Number of animals Dosing regimen Vehicle (10 mL/kg) 4 QW Compound 1 (50mg/kg po) 4 QW Compound 1 (50mg/kg iv) 4 QW Treatment groups Number of animals Dosing regimen ABT-199 (25mg/kg po) 4 QW Compound 3 (12.5mg/kg iv) 4 QW Compound 1 + Compound 3 (po/iv) 4 QW + QW Compound 1 + Compound 3 (iv/iv) 4 QW + QW ABT-199 + Compound 3 (po/iv) 4 QW + QW * Doses are expressed as the free base Primary AML model For this experiment, 32 mice were implanted with primary AML line HAMLX5343. Mice were injected intravenously with 2.0 million leukemia cells. When the tumor burden was n , animals were randomized into eight groups of four mice each for vehicle, nd 1 (po), Compound 1 (iv), ABT-199, Compound 3, or combination treatment. After 18 days of treatment, the study was terminated when the tumor burden reached 99%. Tumor burden was measured by FACS analysis.

Animal monitoring Animal well-being and or, including grooming and ambulation were monitored twice daily. General health of mice was monitored and mortality recorded daily. Any moribund s were sacrificed.

Tumor measurement Mice were bled via tail snip once per week. Blood was split into an IgG control well and a CD33/CD45 well of a 96-well plate. Blood was lysed with 200µl RBC lysis buffer twice at RT, then washed once with FACS buffer (5% FBS in PBS). Samples were then incubated for 10-30 minutes at 4C in 100µl blocking buffer (5% mouse Fc Block + 5% human Fc Block + 90% FACS buffer). 20µl IgG control mix (2.5µl Mouse igG1 K isotype control-PE + 2.5µl Mouse igG1 K isotype control-APC + 15µl FACS ) were added to the IgG control wells and 20ul CD33/CD45 mix (2.5µl Mouse anti-human E + 2.5µl Mouse anti-human CD45-APC + 15µl FACS buffer). Samples were incubated for -60 minutes at 4C then washed twice prior to analysis. Samples were run on Canto with FACSDiva software. Analysis was performed with FloJo software. The percent of CD45- positive, live, single cells was reported as the tumor burden.

Data analysis Percent treatment/control (T/C) values were calculated using the following formula: %T/C = 100 × ΔT/ΔC if ΔT >0 ssion = 100 × ΔT/Tinitial if ΔT <0 where: T = mean tumor burden of the drug-treated group on the final day of the study; ΔT = mean tumor burden of the drug-treated group on the final day of the study – mean tumor burden of the drug-treated group on initial day of dosing; Tinitial = mean tumor burden of the drug-treated group on initial day of dosing; C = mean tumor burden of the control group on the final day of the study; and ΔC = mean tumor burden of the control group on the final day of the study – mean tumor burden of the control group on initial day of .

All data were expressed as Mean ± SEM. Delta tumor burden and body weight were used for statistical analysis. n-groups comparisons for final measurements were performed using ANOVA with Tukey’s test. Statistical analysis was carried out using GraphPad Prism.

Statistical aannaallyyssiiss All data were expressed as mean ± rd error of the mean (SEM). Delta tumor volume and body weight were used for statistical analysis. Between-group comparisons were carried out using the Kruskal-Wallis ANOVA followed by a post hoc Dunn’s test or s test. For all statistical evaluations, the level of significance was set at p < 0.05.

Significance compared to the e control group is reported unless otherwise stated. The standard protocols used in pharmacology studies are not wered to demonstrate statistically significant superiority of a combination over the respective single agent ent. The statistical power is often limited by potent single agent response and/or model variability. The p-values for combination vs single agent treatments are, however, provided.

Results istic anti-tumor effect of combined MCL1 and BCL-2 inhibition In the 7844HAMLX5343-XEF study, Compound 1, ABT-199 or Compound 3 alone did not show anti-tumor activity in the HAMLX5343 model carrying the KRAS mutation, when administered at 50mg/kg (oral or iv), 25mg/kg (oral) or 12.5mg/kg (iv) once a week, respectively (%T/C of 98, 92, 98 or 99%, respectively, p>0.05).

When orally administered, Compound 1 at 50mg/kg or ABT-199 at 25mg/kg in combination with Compound 3 (12.5mg/kg iv) once a week resulted in tumor stasis (%T/C of 3% or 6%, respectively, p<0.05) in this model.

On the other hand, the ation of intravenously administered Compound 1 with Compound 3 induced near complete tumor regression (%Regression of 100%), which is significantly different from either single agent (p<0.05) or nd 1/Compound 3 po/iv combination. The mean tumor burden for each ent group is plotted against time for the 18 day treatment period, as shown in Figure 1. The change in tumor burden, %T/C or %Regression is presented in Table 16 and in Figures 16 ).

Table 16. Summary of anti-tumor effect in 7844HAMLX5343-XEF study ent T/C % Regression % Vehicle 100 Compound 1 50mpk po 98 Compound 1 50mpk iv 92 9 25mpk po 98 Compound 3 12.5mpk iv 99 Compound 1 + Compound 3 (po/iv) Compound 1 + Compound 3 (iv/iv) 100** 9 + Compound 3 (po/iv) * p < 0.05 versus Vehicle and single agents (ANOVA, s test) ** p < 0.05 versus po/iv combination (ANOVA, Tukey’s test) Conclusion AML is an aggressive and heterogeneous hematologic malignancy, caused by the transformation of hematopoietic progenitor cells due to acquisition of genetic alterations (Patel et al, New England Journal of Medicine 2012 366:1079-1089). The 5-year survival rate of AML has been low due to lack of effective therapies. Evasion of apoptosis is a hallmark of cancer (Hanahan et al Cell 2000 100:57-70). One of the primary means by which cancer cells evade apoptosis is by up-regulating the pro-survival BCL-2 family ns such as BCL-2, BCL-xL and MCL1.

MCL1 gene is of the most commonly amplified gene in cancer ts (Beroukhim et al, Nature 2010 463:899-905). Moreover, both BCL-2 and MCL1 are highly expressed in AML. Therefore, the combination of Compound 1 (BCL-2i) and Compound 3 (MCL1) may provide synergy by enhancing pro-apoptotic signals as a general mechanism t We show here that BCL-2 inhibitor Compound 1 or ABT-199 in combination with Compound 3 (MCL1 tor) has a dramatic synergistic effect in treating AML in an AML xenograft model with KRAS mutation (wt FLT3). The iv/iv Compound 1/Compound 3 combination is or to the po/iv combination treatment at the same dose level. The results indicate that the combination of and MCL1 inhibitors would be an effective therapy for AML.

The following numbered paragraphs define particular embodiments of the present disclosure: 1. A combination comprising: (a) a BCL-2 inhibitor of formula (I): Y A2 R5 (I) Rd Rb wherein: ♦ X and Y represent a carbon atom or a en atom, it being understood that they may not simultaneously represent two carbons atoms or two nitrogen atoms, ♦ A1 and A2, together with the atoms carrying them, form an optionally substituted, aromatic or non-aromatic heterocycle Het composed of 5, 6 or 7 ring members which may contain, in on to the nitrogen represented by X or by Y, from one to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched )alkyl group or a group -C(O)-O-Alk n Alk is a linear or branched (C1-C6)alkyl group, or A1 and A2 independently of one another represent a hydrogen atom, a linear or branched )polyhaloalkyl, a linear or branched (C1-C6)alkyl group or a cycloalkyl, ♦ T represents a hydrogen atom, a linear or branched (C1-C6)alkyl group optionally substituted by from one to three halogen atoms, a group (C1-C4)alkyl-NR1R2, or a group (C1-C4)alkyl-OR6, ♦ R1 and R2 independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group, or R1 and R2 form with the nitrogen atom carrying them a heterocycloalkyl, ♦ R3 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched )alkynyl group, a cycloalkyl group, a (C3-C10)cycloalkyl-(C1-C6)alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, it being tood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated, ♦ R4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or ed (C1-C6)alkyl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their le substituents, may be deuterated, ♦ R5 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group, or a linear or ed (C1-C6)alkoxy group, ♦ R6 ents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ Ra, Rb, Rc and Rd, each ndently of the others, represent R7, a n atom, a linear or branched (C1-C6)alkoxy group, a hydroxy group, a linear or branched (C1-C6)polyhaloalkyl group, a trifluoromethoxy group, ', nitro, R7-CO-(C0-C6)alkyl-, R7-CO-NH-(C0-C6)alkyl-, NR7R7'-CO-(C0-C6)alkyl-, NR7R7'-CO-(C0-C6)alkyl-O-, R7-SO2-NH-(C0-C6)alkyl-, R7-NH-CO-NH-(C0-C6)alkyl-, R7-O-CO-NH-(C0-C6)alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (Ra,Rb), (Rb,Rc) or (Rc,Rd) form together with the carbon atoms carrying them a ring composed of from 5 to 7 ring members, which may contain from one to 2 hetero atoms selected from oxygen and sulphur, it also being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from halogen and linear or branched (C1-C6)alkyl, ♦ R7 and R7' independently of one another represent a en, a linear or branched (C1-C6)alkyl, a linear or branched (C2-C6)alkenyl, a linear or branched (C2-C6)alkynyl, an aryl or a heteroaryl, or R7 and R7' together with nitrogen atom ng them form a cycle composed of from 5 to 7 ring members, it being understood that when the compound of formula (I) contains a hydroxy group, the latter may be optionally ted into one of the following groups: M)(OM’), -OPO(OM)(O-M1+), –OPO(O-M1+)(O-M2+), –OPO(O-)(O-)M32+, M)(O[CH2CH2O]nCH3), or –OPO(O-M1+)(O[CH2CH2O]nCH3), wherein M and M' independently of one another represent a hydrogen atom, a linear or ed (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl or a heterocycloalkyl, both composed of from 5 to 6 ring members, while M1+ and M2+ independently of one another represent a pharmaceutically acceptable lent cation, M32+ represents a pharmaceutically acceptable divalent cation, and n is an integer from 1 to 5, it being understood that: - "aryl" means a phenyl, naphthyl, biphenyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens), - "cycloalkyl" means any mono- or lic, non-aromatic, carbocyclic group containing from 3 to 10 ring members, - "heterocycloalkyl" means any mono- or bi-cyclic, non-aromatic, sed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO2 and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy to be substituted by from 1 to 3 groups selected from: linear or branched (C1-C6)alkyl optionally substituted by a hydroxyl, a line, fluoropiperidine or a 3difluoropyrrolidine; (C3-C6)spiro; linear or branched (C1-C6)alkoxy optionally substituted by a morpholine; (C1-C6)alkyl-S-; hydroxyl; oxo; N-oxide; nitro; cyano; -COOR'; -OCOR'; NR'R''; linear or branche d (C1-C6)polyhaloalkyl; trifluoromethoxy; (C1-C6)alkylsulphonyl; halogen; aryl optionally substituted by one or more halogens; heteroaryl; aryloxy; arylthio; cycloalkyl; heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R' and R'' ndently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group optionally substituted by a methoxy, it being possible for the Het group d in formula (I) to be substituted by from one to three groups selected from linear or branched (C1-C6)alkyl, hydroxy, linear or branched (C1-C6)alkoxy, NR1'R1" and n, it being understood that R1' and R1" are as defined for the groups R' and R'' mentioned hereinbefore, or its enantiomers, reoisomers, or addition salts thereof with a pharmaceutically acceptable acid or base, and (b) a MCL1 inhibitor, for simultaneous, sequential or separate use. 2. A ation comprising: (a) a BCL-2 inhibitor and (b) a MCL1 inhibitor of formula (II): wherein: ♦ A represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)alkoxy group, -C6)alkyl group, a linear or branched )polyhaloalkyl, a hydroxy group, a cyano, -NW10W10’, -Cy6 or an halogen atom, ♦ W1, W2, W3, W4 and W5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched )alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a linear or branched (C1-C6)alkoxy group, -S-(C1-C6)alkyl group, a cyano, a nitro group, -alkyl(C0-C6)-NW8W8’, -O-Cy1, -alkyl(C0-C6)-Cy1, -alkenyl(C2-C6)-Cy1, -alkynyl(C2-C6)-Cy1, -O-alkyl(C1-C6)-W9, -C(O)-OW8, -O-C(O)-W8, NW8W8’, -NW8-C(O)-W8’, -NW8-C(O)-OW8’, -alkyl(C1-C6)-NW8-C(O)-W8’, -SO2- NW8W8’, lkyl(C1-C6), or the substituents of one of the pairs (W1, W2), (W2, W3), (W1, W3), (W4, W5) when grafted onto two adjacent carbon atoms, form together with the carbon atoms carrying them an ic or non-aromatic ring composed of from 5 to 7 ring members, which may contain from one to 3 atoms selected from oxygen, sulphur and nitrogen, it being understood that ing ring may be substituted by a group selected from a linear or branched (C1-C6)alkyl group, -NW10W10’, -alkyl(C0-C6)-Cy1 or an oxo, ♦ X’ ents a carbon or a nitrogen atom, ♦ W6 represents a hydrogen, a linear or branched (C1-C8)alkyl group, an aryl, an heteroaryl group, an arylalkyl(C1-C6) group, an heteroarylalkyl(C1-C6) group, ♦ W7 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, (C1-C6)-Cy3, -alkenyl(C2-C6)-Cy3, -alkynyl(C2-C6)-Cy3, -Cy3-Cy4, -alkynyl(C2-C6)-O-Cy3, -Cy3-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy4, an halogen atom, a cyano, -C(O)-W11, -C(O)-NW11W11’, ♦ W8 and W8’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, or -alkyl(C0-C6)-Cy1, or (W8, W8’) form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the en atom from one to 3 heteroatoms selected from , sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a en atom, or a linear or branched )alkyl group and it being understood that one or more of the carbon atoms of the possible substituents, may be deuterated, ♦ W9 ents -Cy1, -Cy1-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)-NW8-alkyl(C0-C6)-Cy2, -Cy1-Cy2-O-alkyl(C0-C6)-Cy5, -C(O)-NW8W8’, -NW8W8’, -OW8,-NW8-C(O)-W8’, -O-alkyl(C1-C6)-OW8, -SO2-W8, -C(O)-OW8, -NH-C(O)-NH-W8, , or , it being possible for the ammonium so defined to exist as a zwitterionic form or to have a monovalent anionic counterion, ♦ W10, W10’, W11 and W11’ independently of one another represent a hydrogen atom or an optionally substituted linear or branched )alkyl group, ♦ W12 represents a hydrogen or a y group, ♦ W13 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ W14 represents a -O-P(O)(O-)(O-) group, a -O-P(O)(O -)(OW 16) group, a -O-P(O)(OW16)(OW16’) group, a -O-SO2-O- group, a -O-SO2-OW16 group, -Cy7, a -O-C(O)-W15 group, a -O-C(O)-OW15 group or a )-NW15W15’ group, ♦ W15 and W15’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or a linear or branched amino(C1-C6)alkyl group, ♦ W16 and W16’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or an arylalkyl(C1-C6) group, ♦ Cy1, Cy2, Cy3, Cy4, Cy5, Cy6 and Cy7 independently of one r, represent a cycloalkyl group, a heterocycloalkyl group, an aryl or an heteroaryl group, ♦ n is an integer equal to 0 or 1, it being understood that: - "aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, - "cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, - “heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may e fused, bridged or spiro ring s, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, l, alkoxy, to be substituted by from 1 to 4 groups selected from linear or branched (C1-C6)alkyl which may be substituted by a group representing a linear or branched (C1-C6)alkoxy which may be tuted by a linear or branched )alkoxy, a linear or ed (C1-C6)polyhaloalkyl, hydroxy, halogen, oxo, -NW’W’’, -O-C(O)-W’, or -CO-NW’W’’; linear or branched (C2-C6)alkenyl group; linear or branched (C2-C6)alkynyl group which may be substituted by a group enting a linear or branched (C1-C6)alkoxy; linear or branched (C1-C6)alkoxy which may be substituted by a group representing a linear or branched (C1-C6)alkoxy, a linear or branched (C1-C6)polyhaloalkyl, a linear or branched (C2-C6)alkynyl, -NW’W’’, or hydroxy; (C1-C6)alkyl-S- which may be substituted by a group representing a linear or branched (C1-C6)alkoxy; hydroxy; oxo; N-oxide; nitro; cyano; OW’; -O-C(O)-W’; ’W’’; -NW’W’’; - (C=NW’)-OW’’; linear or branched (C1-C6)polyhaloalkyl; trifluoromethoxy; or halogen; it being understood that W’ and W’’ independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group which may be tuted by a group representing a linear or branched (C1-C6)alkoxy; and it being understood that one or more of the carbon atoms of the preceding possible substituents, may be deuterated, their enantiomers, diastereoisomers and atropisomers, and on salts thereof with a pharmaceutically acceptable acid or base, for simultaneous, sequential or separate use. 3. A combination according to paragraph 1, wherein the MCL1 inhibitor is a compound of formula (II) as defined in paragraph 2. 4. A combination ing to any of paragraphs 1 to 3, wherein the BCL-2 inhibitor is N- (4-hydroxyphenyl){6-[((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl) yl]-1,3-benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide.

. A combination according to any of paragraphs 1 to 3, wherein the BCL-2 inhibitor is 5- (5-chloro{[(3S)(morpholinylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H- pyrrolecarboxamide. 6. A combination according to paragraph 4, wherein N-(4-hydroxyphenyl){6-[((3S) pholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}- N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide is in the form of the hydrochloride salt. 7. A combination according to aph 5, wherein 5-(5-chloro{[(3S)(morpholin ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl- rolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrolecarboxamide is in the form of the hydrochloride salt. 8. A combination according to paragraph 4 or 6, wherein the dose of N-(4- hydroxyphenyl){6-[((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)- isoquinolinyl)carbonyl]-1,3-benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide during the combination treatment is from 50 mg to 1500 mg. 9. A combination according to any of paragraphs 1 to 8, wherein the BCL-2 inhibitor is administered once a week.

. A combination according to paragraph 6 or 8, wherein N-(4-hydroxyphenyl){6- [((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3- benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide is administered during the combination treatment once a day. 11. A combination according to any of paragraphs 1 to 3, wherein the BCL-2 inhibitor is ABT-199. 12. A combination according to any of paragraphs 1 to 11, wherein the MCL1 inhibitor is -{[(5Sa){3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(5- fluorofuranyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[1-(2,2,2-trifluoroethyl)-1H- pyrazolyl]methoxy}phenyl)propanoic acid. 13. A combination according to any of paragraphs 1 to 11, wherein the MCL1 inhibitor is (2R){[(5Sa){3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(4- fluorophenyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[2-(2-methoxyphenyl)pyrimidin hoxy}phenyl)propanoic acid. 14. A combination according to any of paragraphs 1 to 13, wherein the BCL-2 inhibitor and the MCL1 inhibitor are administered orally.

. A combination according to any of paragraphs 1 to 13, wherein the BCL-2 tor is administered orally and the MCL1 inhibitor is administered intravenously. 16. A combination according to any of aphs 1 to 13, wherein the BCL-2 inhibitor and the MCL1 inhibitor are administered intravenously. 17. A combination according to any of paragraphs 1 to 16, for use in the ent of cancer. 18. The combination for use according to paragraph 17, wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in amounts which are jointly therapeutically effective for the treatment of cancer. 19. The combination for use according to paragraph 17, wherein the BCL-2 inhibitor and the MCL1 tor are provided in amounts which are synergistically effective for the treatment of cancer.

. The combination for use according to paragraph 17, wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in synergistically effective s which enable a reduction of the dose required for each compound in the treatment of cancer, whilst providing an efficacious cancer treatment, with eventually a reduction in side effects. 21. The combination for use according to any of paragraphs 17 to 20, wherein the cancer is leukaemia. 22. The combination for use according to paragraph 21, wherein the leukaemia is acute myeloid leukaemia, T-ALL or B-ALL. 23. The combination for use according to any of aphs 17 to 20, wherein the cancer is myelodysplastic me or myeloproliferative disease. 24. The combination for use according to any of paragraphs 17 to 20, wherein the cancer is lymphoma.

. The combination for use according to paragraph 24, wherein the lymphoma is a non-Hodgkin ma. 26. The combination for use ing to paragraph 25, wherein the dgkin lymphoma is diffuse large B-cell lymphoma or mantle-cell lymphoma. 27. The combination for use according to any of paragraphs 17 to 20, wherein the cancer is multiple myeloma. 28. The combination for use according to any of paragraphs 17 to 20, wherein the cancer is neuroblastoma. 29. The combination for use according to any of paragraphs 17 to 20, wherein the cancer is small cell lung cancer.

. A ation according to any of paragraphs 1 to 16, further comprising one or more excipients. 31. The use of a combination according to any of paragraphs 1 to 16, in the manufacture of a medicament for the treatment of cancer. 32. The use according to paragraph 31, wherein the cancer is leukaemia. 33. The use according to paragraph 32, wherein the leukaemia is acute d leukaemia, T-ALL or B-ALL. 34. The use according to paragraph 31, wherein the cancer is ysplastic syndrome or myeloproliferative e.

. The use according to paragraph 31, wherein the cancer is lymphoma. 36. The use according to paragraph 35, wherein the lymphoma is a non-Hodgkin lymphoma. 37. The use ing to paragraph 36, wherein the non-Hodgkin lymphoma is e large B-cell lymphoma or mantle-cell lymphoma. 38. The use ing to paragraph 31, wherein the cancer is multiple myeloma. 39. The use according to paragraph 31, wherein the cancer is neuroblastoma. 40. The use according to paragraph 31, wherein the cancer is small cell lung cancer. 41. A medicament containing, separately or together, (a) a BCL-2 inhibitor of formula (I) as defined in paragraph 1, and (b) a MCL1 inhibitor, for simultaneous, tial or separate administration, and wherein the BCL-2 inhibitor and the MCL1 inhibitor are ed in ive amounts for the treatment of cancer. 42. A medicament containing, separately or er, (a) a BCL-2 tor, and (b) a MCL1 inhibitor of formula (II) as defined in paragraph 2, for simultaneous, sequential or separate administration, and wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in effective amounts for the treatment of cancer. 43. A method of treating cancer, comprising administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor of formula (I) as defined in paragraph 1, and (b) a MCL1 tor, to a subject in need thereof. 44. A method of ng cancer, comprising administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of formula (II) as defined in aph 2, to a subject in need thereof. 45. A method for sensitizing a patient who is (i) refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii), wherein the method comprises administering a y therapeutically effective amount of (a) a BCL-2 inhibitor of formula (I) as defined in paragraph 1, and (b) a MCL1 inhibitor, to said patient. 46. A method for sensitizing a patient who is (i) refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii), wherein the method comprises administering a jointly therapeutically ive amount of (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of a (II) as defined in paragraph 2, to said patient.

Claims (28)

1. A combination comprising: (a) a BCL-2 inhibitor of formula (I): Y A2 R5 (I) Rd Rb wherein: 5 ♦ X and Y represent a carbon atom or a nitrogen atom, it being understood that they may not simultaneously represent two carbons atoms or two nitrogen atoms, ♦ A1 and A2, together with the atoms carrying them, form an optionally substituted, aromatic or non-aromatic heterocycle Het composed of 5, 6 or 7 ring s which may contain, in addition to the nitrogen ented by X or by Y, from one 10 to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in on may be substituted by a group enting a en atom, a linear or branched (C1-C6)alkyl group or a group -C(O)-O-Alk wherein Alk is a linear or branched (C1-C6)alkyl group, or A1 and A2 independently of one another represent a hydrogen atom, a linear or 15 branched (C1-C6)polyhaloalkyl, a linear or branched (C1-C6)alkyl group or a cycloalkyl, ♦ T represents a hydrogen atom, a linear or branched (C1-C6)alkyl group ally substituted by from one to three halogen atoms, a group (C1-C4)alkyl-NR1R2, or a group (C1-C4)alkyl-OR6, ♦ R1 and R2 ndently of one another represent a hydrogen atom or a linear or branched )alkyl group, or R1 and R2 form with the nitrogen atom carrying them a heterocycloalkyl, ♦ R3 represents a linear or branched )alkyl group, a linear or branched 5 (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl group, a (C3-C10)cycloalkyl-(C1-C6)alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated, 10 ♦ R4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched (C1-C6)alkyl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated, ♦ R5 represents a hydrogen or halogen atom, a linear or ed (C1-C6)alkyl group, or a linear or branched (C1-C6)alkoxy group, 15 ♦ R6 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ♦ Ra, Rb, Rc and Rd, each independently of the others, represent R7, a n atom, a linear or branched (C1-C6)alkoxy group, a hydroxy group, a linear or branched (C1-C6)polyhaloalkyl group, a trifluoromethoxy group, -NR7R7', nitro, (C0-C6)alkyl-, R7-CO-NH-(C0-C6)alkyl-, NR7R7'-CO-(C0-C6)alkyl-, 20 NR7R7'-CO-(C0-C6)alkyl-O-, R7-SO2-NH-(C0-C6)alkyl-, R7-NH-CO-NH-(C0-C6)alkyl-, O-NH-(C0-C6)alkyl-, a heterocycloalkyl group, or the tuents of one of the pairs (Ra,Rb), (Rb,Rc) or (Rc,Rd) form together with the carbon atoms carrying them a ring ed of from 5 to 7 ring members, which may contain from one to 2 hetero atoms selected from oxygen and 25 sulphur, it also being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from n and linear or branched (C1-C6)alkyl, ♦ R7 and R7' independently of one another represent a hydrogen, a linear or branched (C1-C6)alkyl, a linear or branched (C2-C6)alkenyl, a linear or branched 30 (C2-C6)alkynyl, an aryl or a heteroaryl, or R7 and R7' together with nitrogen atom carrying them form a heterocycle composed of from 5 to 7 ring members, it being understood that when the nd of formula (I) contains a y group, the latter may be optionally ted into one of the following groups: –OPO(OM)(OM’), -OPO(OM)(O-M1+), –OPO(O-M1+)(O-M2+), –OPO(O-)(O-)M32+, –OPO(OM)(O[CH2CH2O]nCH3), or –OPO(O-M1+)(O[CH2CH2O]nCH3), wherein M and M' 5 independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl or a heterocycloalkyl, both composed of from 5 to 6 ring members, while M1+ and M2+ independently of one r ent a pharmaceutically acceptable monovalent cation, M32+ represents a pharmaceutically acceptable divalent cation, and n is 10 an integer from 1 to 5, it being tood that: - "aryl" means a phenyl, naphthyl, biphenyl or indenyl group, - oaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero 15 atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens), - "cycloalkyl" means any mono- or bi-cyclic, non-aromatic, yclic group containing from 3 to 10 ring members, - "heterocycloalkyl" means any mono- or bi-cyclic, non-aromatic, condensed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms 20 selected from oxygen, sulphur, SO, SO2 and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and cycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy to be substituted by from 1 to 3 groups selected from: linear or branched (C1-C6)alkyl ally substituted by a hydroxyl, a morpholine, 3difluoropiperidine or a 3difluoropyrrolidine; (C3-C6)spiro; linear or 25 branched (C1-C6)alkoxy ally substituted by a morpholine; (C1-C6)alkyl-S-; hydroxyl; oxo; N-oxide; nitro; cyano; -COOR'; -OCOR'; NR'R''; linear or branche d (C1-C6)polyhaloalkyl; trifluoromethoxy; (C1-C6)alkylsulphonyl; halogen; aryl optionally substituted by one or more halogens; heteroaryl; aryloxy; io; cycloalkyl; heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R' and R'' independently of one another represent a en atom or a linear or branched (C1-C6)alkyl group optionally substituted by a methoxy, it being possible for the Het group defined in formula (I) to be substituted by from one to three groups selected from linear or ed (C1-C6)alkyl, hydroxy, linear or branched 5 (C1-C6)alkoxy, NR1'R1" and halogen, it being understood that R1' and R1" are as defined for the groups R' and R'' mentioned hereinbefore, or its enantiomers, diastereoisomers, or addition salts thereof with a pharmaceutically acceptable acid or base, and (b) a MCL1 inhibitor, 10 for simultaneous, tial or separate use.

2. A combination comprising: (a) a BCL-2 inhibitor and (b) a MCL1 tor of formula (II): 15 wherein: ♦ A represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)alkoxy group, -S-(C1-C6)alkyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a cyano, -NW10W10’, -Cy6 or an halogen atom, ♦ W1, W2, W3, W4 and W5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched 5 (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a linear or branched (C1-C6)alkoxy group, -S-(C1-C6)alkyl group, a cyano, a nitro group, -alkyl(C0-C6)-NW8W8’, -O-Cy1, -alkyl(C0-C6)-Cy1, -alkenyl(C2-C6)-Cy1, -alkynyl(C2-C6)-Cy1, -O-alkyl(C1-C6)-W9, -C(O)-OW8, -O-C(O)-W8, 10 -C(O)-NW8W8’, -NW8-C(O)-W8’, -NW8-C(O)-OW8’, -alkyl(C1-C6)-NW8-C(O)-W8’, -SO2- NW8W8’, -SO2-alkyl(C1-C6), or the substituents of one of the pairs (W1, W2), (W2, W3), (W1, W3), (W4, W5) when grafted onto two adjacent carbon atoms, form together with the carbon atoms carrying them an ic or non-aromatic ring composed of from 5 to 7 ring 15 members, which may contain from one to 3 heteroatoms selected from oxygen, r and nitrogen, it being understood that resulting ring may be substituted by a group ed from a linear or branched (C1-C6)alkyl group, -NW10W10’, -alkyl(C0-C6)-Cy1 or an oxo, ♦ X’ represents a carbon or a nitrogen atom, 20 ♦ W6 represents a hydrogen, a linear or branched (C1-C8)alkyl group, an aryl, an heteroaryl group, an arylalkyl(C1-C6) group, an heteroarylalkyl(C1-C6) group, ♦ W7 represents a linear or branched )alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, -alkyl(C1-C6)-Cy3, -alkenyl(C2-C6)-Cy3, -alkynyl(C2-C6)-Cy3, -Cy3-Cy4, 25 -alkynyl(C2-C6)-O-Cy3, -Cy3-alkyl(C0-C6)-O-alkyl(C0-C6)-Cy4, an halogen atom, a cyano, -C(O)-W11, -C(O)-NW11W11’, ♦ W8 and W8’ ndently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, or -alkyl(C0-C6)-Cy1, or (W8, W8’) form together with the en atom ng them an aromatic or 30 non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from one to 3 heteroatoms ed from oxygen, r and en, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, or a linear or branched (C1-C6)alkyl group and it being tood that one or more of the carbon atoms of the possible substituents, may be ated, ♦ W9 represents -Cy1, -Cy1-alkyl(C0-C6)-Cy2, lkyl(C0-C6)-O-alkyl(C0-C6)-Cy2, 5 -Cy1-alkyl(C0-C6)-NW8-alkyl(C0-C6)-Cy2, -Cy1-Cy2-O-alkyl(C0-C6)-Cy5, NW8W8’, -NW8W8’, -OW8,-NW8-C(O)-W8’, yl(C1-C6)-OW8, -SO2-W8, -C(O)-OW8, -NH-C(O)-NH-W8, , or , it being possible for the ammonium so defined to exist as a zwitterionic form or to 10 have a monovalent anionic counterion, ♦ W10, W10’, W11 and W11’ independently of one another represent a hydrogen atom or an ally substituted linear or branched (C1-C6)alkyl group, ♦ W12 represents a hydrogen or a hydroxy group, ♦ W13 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, 15 ♦ W14 represents a -O-P(O)(O-)(O-) group, a -O-P(O)(O -)(OW 16) group, a -O-P(O)(OW16)(OW16’) group, a -O-SO2-O- group, a -O-SO2-OW16 group, -Cy7, a -O-C(O)-W15 group, a -O-C(O)-OW15 group or a )-NW15W15’ group, ♦ W15 and W15’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or a linear or branched amino(C1-C6)alkyl group, 20 ♦ W16 and W16’ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or an arylalkyl(C1-C6) group, ♦ Cy1, Cy2, Cy3, Cy4, Cy5, Cy6 and Cy7 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl or an heteroaryl group, ♦ n is an integer equal to 0 or 1, 25 it being understood that: - "aryl" means a phenyl, naphthyl, biphenyl, l or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, - "cycloalkyl" means any mono- or bi-cyclic omatic carbocyclic group containing from 3 to 10 ring members, - “heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group 5 containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, d or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy, to be substituted by from 1 to 4 groups 10 selected from linear or ed (C1-C6)alkyl which may be substituted by a group representing a linear or branched (C1-C6)alkoxy which may be substituted by a linear or branched (C1-C6)alkoxy, a linear or branched (C1-C6)polyhaloalkyl, hydroxy, halogen, oxo, -NW’W’’, -O-C(O)-W’, or -CO-NW’W’’; linear or branched (C2-C6)alkenyl group; linear or branched (C2-C6)alkynyl group which may be 15 substituted by a group enting a linear or branched (C1-C6)alkoxy; linear or branched (C1-C6)alkoxy which may be substituted by a group representing a linear or branched (C1-C6)alkoxy, a linear or branched (C1-C6)polyhaloalkyl, a linear or branched (C2-C6)alkynyl, -NW’W’’, or hydroxy; (C1-C6)alkyl-S- which may be substituted by a group representing a linear or ed (C1-C6)alkoxy; hydroxy; oxo; 20 N-oxide; nitro; cyano; -C(O)-OW’; -O-C(O)-W’; ’W’’; -NW’W’’; - (C=NW’)-OW’’; linear or branched (C1-C6)polyhaloalkyl; trifluoromethoxy; or halogen; it being understood that W’ and W’’ independently of one r represent a hydrogen atom or a linear or branched (C1-C6)alkyl group which may be substituted by a group representing a linear or branched (C1-C6)alkoxy; and it being understood 25 that one or more of the carbon atoms of the ing possible substituents, may be deuterated, their enantiomers, diastereoisomers and atropisomers, and addition salts thereof with a ceutically acceptable acid or base, for simultaneous, tial or separate use.

3. A combination according to claim 1, wherein the MCL1 inhibitor is a compound of formula (II) as defined in claim 2.

4. A ation according to any of claims 1 to 3, n the BCL-2 inhibitor is N-(4- hydroxyphenyl){6-[((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl) 5 carbonyl]-1,3-benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide.

5. A combination according to any of claims 1 to 3, wherein the BCL-2 inhibitor is 5-(5- {[(3S)(morpholinylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H- pyrrolecarboxamide. 10

6. A combination according to claim 4, wherein ydroxyphenyl){6-[((3S)(4- morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxolyl}-N- phenyl-5,6,7,8-tetrahydroindolizine carboxamide is in the form of the hydrochloride salt.

7. A combination according to claim 5, wherein 5-(5-chloro{[(3S)(morpholin 15 ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl- 1H-pyrrolyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrolecarboxamide is in the form of the hydrochloride salt.

8. A combination according to claim 4 or 6, wherein the dose of N-(4-hydroxyphenyl) {6-[((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3- 20 ioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide during the combination treatment is from 50 mg to 1500 mg.

9. A combination according to any of claims 1 to 8, wherein the BCL-2 inhibitor is administered once a week.

10. A combination according to claim 6 or 8, wherein N-(4-hydroxyphenyl){6- [((3S)(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3- benzodioxolyl}-N-phenyl-5,6,7,8-tetrahydroindolizine carboxamide is administered during the combination treatment once a day. 5

11. A ation according to any of claims 1 to 3, wherein the BCL-2 inhibitor is ABT-199.

12. A combination according to any of claims 1 to 11, wherein the MCL1 inhibitor is (2R){[(5Sa){3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(5- fluorofuranyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[1-(2,2,2-trifluoroethyl)-1H- 10 pyrazolyl]methoxy}phenyl)propanoic acid.

13. A combination according to any of claims 1 to 11, wherein the MCL1 inhibitor is -{[(5Sa){3-chloromethyl[2-(4-methylpiperazinyl)ethoxy]phenyl}(4- fluorophenyl)thieno[2,3-d]pyrimidinyl]oxy}(2-{[2-(2-methoxyphenyl)pyrimidin yl]methoxy}phenyl)propanoic acid. 15

14. A combination ing to any of claims 1 to 13, wherein the BCL-2 inhibitor and the MCL1 inhibitor are administered orally.

15. A combination ing to any of claims 1 to 13, wherein the BCL-2 tor is administered orally and the MCL1 inhibitor is administered intravenously. 20

16. A combination according to any of claims 1 to 13, wherein the BCL-2 inhibitor and the MCL1 inhibitor are administered intravenously.

17. A combination according to any of claims 1 to 16, for use in the treatment of cancer.

18. The combination for use according to claim 17, wherein the BCL-2 inhibitor and 25 the MCL1 inhibitor are provided in amounts which are jointly eutically effective for the treatment of ; or wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in amounts which are synergistically effective for the treatment of cancer; or wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in synergistically effective amounts which enable a reduction of the dose required for each compound in the 5 treatment of cancer, whilst providing an efficacious cancer treatment, with eventually a reduction in side s.

19. The combination for use according to claim 17 or 18, wherein the cancer is leukaemia, optionally wherein the leukaemia is acute myeloid leukaemia, T-ALL or BALL ; or wherein the cancer is myelodysplastic syndrome or myeloproliferative disease; or 10 wherein the cancer is lymphoma, ally wherein the lymphoma is a non-Hodgkin lymphoma, optionally wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma or mantle-cell lymphoma; or wherein the cancer is multiple myeloma; or wherein the cancer is neuroblastoma; or wherein the cancer is small cell lung cancer.

20. A combination according to any of claims 1 to 16, r comprising one or more 15 excipients.

21. The use of a combination according to any of claims 1 to 16, in the manufacture of a medicament for the treatment of cancer.

22. The use according to claim 21, n the cancer is leukaemia, optionally wherein the leukaemia is acute myeloid leukaemia, T-ALL or B-ALL; or wherein the cancer is 20 myelodysplastic syndrome or myeloproliferative disease; or wherein the cancer is lymphoma, optionally wherein the lymphoma is a non-Hodgkin lymphoma, optionally wherein the non-Hodgkin lymphoma is e large B-cell lymphoma or mantle-cell lymphoma; or wherein the cancer is multiple myeloma; or wherein the cancer is neuroblastoma; or wherein the cancer is small cell lung . 25

23. A medicament containing, tely or er, (a) a BCL-2 inhibitor of a (I) as defined in claim 1, and (b) a MCL1 inhibitor, for simultaneous, tial or separate administration, and wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in effective amounts for the treatment of cancer.

24. A medicament containing, tely or together, (a) a BCL-2 inhibitor, and 5 (b) a MCL1 inhibitor of a (II) as defined in claim 2, for simultaneous, sequential or separate administration, and wherein the BCL-2 inhibitor and the MCL1 inhibitor are provided in effective s for the treatment of cancer.

25. A method of treating cancer, comprising administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor of formula (I) as defined in claim 1, and 10 (b) a MCL1 inhibitor, to a subject in need thereof.

26. A method of treating cancer, comprising administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of formula (II) as defined in claim 2, 15 to a subject in need thereof.

27. A method for sensitizing a patient who is (i) refractory to at least one chemotherapy treatment, or (ii) in e after treatment with chemotherapy, or both (i) and (ii), wherein the method ses administering a jointly therapeutically effective amount of (a) a BCL-2 tor of formula (I) as defined in claim 1, and (b) a MCL1 inhibitor, to said 20 patient.

28. A method for sensitizing a patient who is (i) refractory to at least one chemotherapy ent, or (ii) in e after treatment with chemotherapy, or both (i) and (ii), wherein the method comprises administering a jointly therapeutically effective amount of (a) a BCL-2 inhibitor, and (b) a MCL1 inhibitor of formula (II) as defined in claim 2, to said 25 patient.